Using Light to Observe and Control Cellular Function: Improving Bioluminescence Imaging and Photocontrol of Rho GTPase Activation States: A Dissertation by Harwood, Katryn R.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2011-09-30 
Using Light to Observe and Control Cellular Function: Improving 
Bioluminescence Imaging and Photocontrol of Rho GTPase 
Activation States: A Dissertation 
Katryn R. Harwood 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, and the Cellular and 
Molecular Physiology Commons 
Repository Citation 
Harwood KR. (2011). Using Light to Observe and Control Cellular Function: Improving Bioluminescence 
Imaging and Photocontrol of Rho GTPase Activation States: A Dissertation. GSBS Dissertations and 
Theses. https://doi.org/10.13028/k5sh-t587. Retrieved from https://escholarship.umassmed.edu/
gsbs_diss/569 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
USING LIGHT TO OBSERVE AND CONTROL CELLULAR FUNCTION: 
Improving Bioluminescence Imaging and Photocontrol of Rho GTPase Activation 
States 
 
 
A Dissertation Presented 
 
By 
 
KATRYN RENÉE HARWOOD 
 
 
Submitted to the Faculty of the  
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
In partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
September 30, 2011 
Biochemistry and Molecular Pharmacology 
 
 
USING LIGHT TO OBSERVE AND CONTROL CELLULAR FUNCTION: Improving 
Bioluminescence Imaging and Photocontrol of Rho GTPase Activation States 
A Dissertation Presented 
By 
KATRYN RENÉE HARWOOD 
The signatures of the Dissertation Defense Committee signify                            
completion and approval as to style and content of the Dissertation 
 
______________________________________ 
Stephen Miller, Ph.D., Thesis Advisor 
 
__________________________________________ 
William Kobertz, Ph.D., Member of Committee 
 
__________________________________________ 
Kirsten Hagstrom, Ph.D., Member of Committee 
 
__________________________________________ 
David Lambright, Ph.D., Member of Committee 
 
__________________________________________ 
Bruce Branchini, Ph.D., Member of Committee 
 
 
The signature of the Chair of the Committee signifies that the written dissertation meets 
the requirements of the Dissertation Committee 
 
__________________________________________ 
Kendall Knight, Ph.D., Chair of Committee 
  
The signature of the Dean of the Graduate School of Biomedical Sciences signifies      
that the student has met all graduation requirements of the school 
 
__________________________________________ 
Anthony Carruthers, Ph.D.,  
Dean of the Graduate School of Biomedical Sciences 
 
Program in Biochemistry and Molecular Pharmacology 
September 30, 2011 
 iii 
DEDICATION 
 
 I dedicate this thesis to my wonderful family--my mother and father, Janice and 
Jim Harwood, my brother, Brad Harwood, and my fiancé Mina Seedhom.  Your love and 
support have been immense. 
 
 iv 
ACKNOWLEDGEMENTS 
 
 First, I would like to acknowledge my thesis advisor, Stephen Miller, without 
whom this thesis would not be possible.  He gave me a second chance with my first 
project:  I loved photocaging Rho GTPases and learned so much.  I also have to thank 
him for giving me the opportunity to work on luciferase, which was just so much pure 
fun experimentally.  Your guidance over the years has shaped me as a scientist. 
I am very appreciative of my committee members, Kendall Knight, Bill Kobertz, 
Kirsten Hagstrom, and David Lambright, who have been very supportive during my time 
as a graduate student.  I am very grateful to Bruce Branchini for serving as my outside 
committee member.  I really appreciate him taking the time to be part of this process. 
Also, a huge thanks to Natalie Wayne and her P.I. Dan Bolon for all of their help 
with protein purification and efforts to generate full length Rho GTPases.  Natalie was a 
great teacher and colleague throughout graduate school.  In addition, I must thank Jinal 
Patel and Karin Green for all of their help with mass spectrometry over the years.   
Thank you as well to my lab mates and to my “step”-lab mates in the Kobertz lab 
for your invaluable help over the years.  Steven Pauff and Karen Mruk, a profound thank 
you for lending your shoulders, and homes, to me when I needed them most.  I also have 
to thank my incredible family and the great friends I met here at UMass for always being 
there for me.  I love you all.  Finally, I thank my amazing fiancé; your support during our 
time in graduate school has meant the world to me (and a nickel!).$ 
                                                 
$ Dee 
 v 
ABSTRACT 
 
The dynamic processes that occur at specific times and locations in cells and/or 
whole organisms during cellular division, migration, morphogenesis and development are 
critical.  When these molecular events are not properly regulated, disease states can 
develop.  Tools that can allow us to better understand the specific events that, when 
misregulated, result in disease development can also allow us to determine better ways to 
combat such misregulation.  Specifically, tools that could allow us to better visualize 
cellular processes or those that allow us to control cellular functioning in a 
spatiotemporal manner could present great insight into the detailed inner workings of 
cells and/or whole organisms.  Where chemistry and biology intersect presents a 
powerful starting point for the development of such tools.    
The first half of this thesis addresses tools to allow the better visualization of 
cellular events, in particular the intriguing process of bioluminescence and the work that 
has been done to better understand and optimize its utilization, particularly in living 
organisms.  The novel work presented here details a parallel approach to improve our 
ability to observe cellular functioning specifically by improving bioluminescence 
imaging through the generation and characterization of mutant luciferase proteins that 
can better utilize novel small molecule luciferin substrates.   
The second half of this thesis discusses methods that have been developed to 
better control cellular events through the control of protein activity, specifically a family 
of proteins called the Rho GTPases.  This family’s activation at specific times and 
 vi 
locations is essential to proper cellular function and exemplifies the need for 
spatiotemporal control.  Described are methods to control the activation states of the Rho 
GTPases to probe their cellular roles in a temporal and spatial manner using 
photosensitive small molecules.  Taken together, the findings described herein 
demonstrate the application of chemistry to allow for the better observation and control 
of cellular processes, toward the ultimate goal of improving our understanding of the 
regulatory processes involved in the control of key factors leading to disease states. 
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CHAPTER 1: Improving Bioluminescence Imaging Background 
 
Introduction 
 Bioluminescence is a fascinating process by which an organism converts the 
energy of a chemical reaction into light.  While many different species possess 
bioluminescent properties, including bacteria, fungi, and fish (Greer and Szalay, 2002; 
Johnson and Shimomura, 1972; Shimomura, 2006), the most commonly studied have 
been bioluminescent beetles.  As many as 2000 different species of bioluminescent beetle 
have been observed (Hastings, 1995; Lloyd, 1978a), with the North American firefly 
Photinus pyralis the best characterized (Deluca, 1976).  These fireflies use the flashing 
light derived from the bioluminescent reaction to signal to potential mates, with different 
species adopting distinct patterns of flashes (Lloyd, 1978b). 
The bioluminescence of the firefly relies on the chemical reaction between the 
luciferin substrate, ATP and oxygen in the context of the binding pocket of the luciferase 
enzyme to generate light (Figure 1-1).  Specifically, in the presence of ATP-Mg2+, 
luciferase converts luciferin to luciferyl-AMP, with the displacement of inorganic 
pyrophosphate.  Removal of a proton from the C-4 carbon of the adenylate and addition 
of molecular oxygen transforms luciferyl-AMP into the very reactive dioxetanone 
intermediate, which possesses a strained four-membered cyclic ring that spontaneously 
breaks down to generate the excited state oxyluciferin and carbon dioxide (Deluca, 1976; 
White et al., 1971; White et al., 1980).  Light is emitted upon relaxation of the excited 
state oxyluciferin molecule back to the ground state (Suzuki and Goto, 1972; Suzuki et 
 2 
al., 1969).  In addition, a dark reaction pathway in which luciferyl-AMP reacts with 
oxygen to generate the oxidized product dehydroluciferyl-AMP can also occur (Rhodes 
and McElroy, 1958). 
 
 
 
 
 
Figure 1-1.  Luciferase mechanism. Firefly luciferase catalyzes the formation of an 
activated AMP ester of its native substrate, D-luciferin. Subsequent oxidation within the 
luciferase binding pocket generates an excited state oxyluciferin molecule that is 
responsible for light emission. 
 
 
The quantum yield of luciferase catalyzed light emission is very high and was 
originally reported to be 0.88 (Seliger and Mc, 1960), meaning that the ratio of reacted 
luciferin to photons of light emitted was initially thought to be almost 1:1.  Using a newly 
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developed total-photon-flux spectrometer, which allowed for a more accurate 
determination of the quantum yield, Ando and colleagues reported the quantum yield 
from the American firefly Photinus pyralis to be a more modest but still quite high ~0.41 
(Ando et al., 2008; Kazuki et al., 2007).  This is especially impressive when compared to 
the quantum yields possible for most chemiluminescent reactions, which are typically 
~0.01 (Roda et al., 2009). 
 Firefly luciferase is a member of the acyl-adenylate/thioester-forming superfamily 
of enzymes that also includes many acyl-CoA ligases (Babbitt et al., 1992; Chang et al., 
1997; Suzuki et al., 1990).  Crystal structures of the luciferase proteins and other acyl-
adenylate forming enzymes reveal a common structural motif made up of two domains, a 
larger N-terminal domain and a smaller C-terminal domain, linked by a flexible linker 
peptide (Conti et al., 1997; Franks et al., 1998; Gulick et al., 2003; May et al., 2002; 
Nakatsu et al., 2006). Luciferase functions as a monomer of about 61 kDa (de Wet et al., 
1985), and does not possess any functionally significant posttranslational modifications 
or disulfide bonds (Alter and DeLuca, 1986; DeLuca et al., 1964).  Further, the full length 
enzyme is fully active directly following translation from its mRNA (Wood et al., 1984), 
and protein expressed from E. coli behaves in a manner that is indistinguishable from the 
native luciferase (Hill et al., 1986). 
 Luciferase-based assays have broad applications in the study of mammalian 
biology.  Due to the role ATP plays in the luminescent reaction, firefly luciferase has 
been widely used as a tool to measure ATP concentrations (Ludin, 1981). Expression of 
luciferase in E. coli (de Wet et al., 1985) and cloning of the full-length gene (Cohn et al., 
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1983; de Wet et al., 1987) expanded the application of luciferase to the study of protein 
metabolism and gene expression in mammalian cells.  Furthermore, unlike fluorescence-
based methods, bioluminescence does not require exogenous illumination.  This means 
that in imaging studies using luciferase, background is greatly reduced, improving 
sensitivity.   
The many applications of firefly luciferase assays have included the detection of 
bacteria and environmental toxins (Alexander et al., 2000; Campbell and Sala-Newby, 
1993; Kricka, 2000; Roda et al., 2004; Squirrel et al., 2002), gene expression and 
regulation studies (de Ruijter et al., 2003; Gelmini et al., 2000; Gould and Subramani, 
1988), monitoring of biomolecular interactions using bioluminescence resonance energy 
transfer (BRET) (Arai et al., 2002; Prinz et al., 2006; Xia and Rao, 2009; Yamakawa et 
al., 2002), and many others.  Firefly luciferase has also been used for genetic regulation 
studies and the monitoring of tumor growth and metastasis in whole organisms (Contag 
and Bachmann, 2002; Contag et al., 1997; Rehemtulla et al., 2000; Yu et al., 2003). 
The high relative quantum yield of light emission of the luciferase:luciferin 
reaction and its inherently low background make luciferase bioluminescence a 
particularly powerful tool for cellular imaging.  However, at physiological pH, firefly 
luciferase emits yellow-green light (max 560 nm).  Light of this wavelength exhibits poor 
tissue penetrance in whole organisms, and further can be absorbed by hemoglobin, 
melanin and other pigmented cellular components.  Light above 600 nm in wavelength, 
however, is absorbed less strongly than shorter wavelength light and can travel a greater 
distance through tissue (Cheong et al., 1990; Villalobos et al., 2007; Zhao et al., 2005).  
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The emission of longer wavelengths of light from luciferase would greatly improve the 
utilization of bioluminescence imaging in intact tissues and whole organisms.  
 
Naturally occurring luciferases that emit red-shifted light 
In nature, beetles have been observed to emit light of many different colors 
ranging from green (~540 nm) to red (~635 nm) (Hastings, 1996; McElroy and Seliger, 
1966).   It has been suggested that the evolution of luciferases that emit in this wide range 
was to optimize detection under certain photic conditions or for distinct biological 
functions (Lall et al., 1980).  The differences in bioluminescence color seen in the 
different beetle species are caused by the natural species variations in luciferase structure, 
as all use the same luciferin substrate, D-luciferin (Hastings, 1996; McElroy and Seliger, 
1966; Wood, 1995; Wood et al., 1989b).  The different beetle luciferases that have been 
cloned include those from fireflies (Lampyridae), click beetles (Elateridae), railroad 
worms (Phengodidae), and Japanese luminous beetles (Rhagophthalmidae) (Ugarova and 
Brovko, 2002; Welsh and Noguchi, 2010).  Of these, fireflies emit green-yellow light 
(Biggley et al., 1967; Seliger et al., 1964), click beetles emit green-orange light (Biggley 
et al., 1967; Colepicolo et al., 1986), and railroad worms emit green-red light (Viviani 
and Bechara, 1993, 1997).  
The Jamaican click beetle Pyrophorus plagiophthalamus is particularly 
interesting in that it has two sets of light producing organs, a ventral organ and a pair of 
organs on the dorsal surface of the prothorax.  While the dorsal pair emits light ranging 
from green to yellow green, the ventral organ emits that ranging from green to orange, 
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with overall emission ranging from 547-594 nm (Biggley et al., 1967).  Another 
fascinating species are the Phrixothrix railroad worms.  They emit yellow-green light 
(max 542-574) from dorsal lateral lanterns along the body, and red light (max 609-635) 
from cephalic and post cephalic organs (Viviani and Bechara, 1993, 1997). 
Other notable non-beetle luciferases that have been cloned are those from several 
marine species, including the sea pansy Renilla reniformis (max 480) (Lorenz et al., 
1991) and the copepod Gaussia princeps (max 480) (Tannous et al., 2005).  These differ 
from the beetle luciferases in that they are smaller, ATP-independent, and their substrate 
is not D-luciferin but coelenterazine.  From a reagent perspective, relative to D-luciferin 
coelenterazine is more toxic and expensive, and less stable and soluble.  It also is more 
autoluminescent than D-luciferin, increasing the background observed and reducing 
sensitivity (Welsh and Noguchi, 2010).   
Interestingly, under certain conditions, the light emitted from firefly luciferases is 
shifted to the red as well.  Some of these conditions include a shift in pH from neutral to 
acidic, temperature increase, or the presence of ATP analogs or certain divalent metal 
ions such as Hg2+ and Zn2+ (Deluca, 1976; McElroy et al., 1965; Rosendahl et al., 1982; 
Seliger and McElroy, 1964; Viviani, 2002; Viviani et al., 2008; Wood et al., 1989a; 
Wood et al., 1989c).  Unlike firefly luciferases, railroad worm and click beetle luciferases 
are not sensitive to pH dependent changes with respect to the color of emitted light 
(Viviani and Bechara, 1995).  To begin to understand the factors that lead to the different 
colors emitted from different species’ luciferases, as well as the effect of pH on the color 
change seen with firefly luciferase under acidic conditions, much work has been done 
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with native species of luciferase, as well as genetically engineered chimeras and mutants 
proteins.  
 
Studies of red emitting native, chimeric and mutant luciferases 
While it was first observed in 1964 that the click beetles of Jamaica (Pyrophorus 
plagiophthalamus) displayed different profiles of light emission than North American 
fireflies (Seliger and McElroy, 1964), due to the limited availability of the beetles 
themselves, it was not until several years later that Wood and colleagues isolated cDNA 
from them and determined that they coded for four different luciferase homologs.  These 
homologs possess between 94-99% amino acid identity and each displays a different 
color of light emission ranging from green to orange (max 546, 560, 578, 593 nm) (Wood 
et al., 1989c).  Chimeras, or “rearrangement hybrids”, of these proteins were generated by 
exchanging restriction fragments from the different clones and single mutants were made 
by site directed mutagenesis to yield 31 recombinant luciferases in an attempt to 
determine which specific amino acid changes could account for the color changes 
observed (Wood, 1990; Wood et al., 1989b).  From this analysis, two sets of amino acid 
changes were found to cause a red shift in the color of light emitted, the pair 
R223E/L238V and the set S247G/D352V/S358T.  Similarly, chimeric mutants of the 
luciferases from the fireflies Pyrocoelia miyako (max 550 nm) and Hotaria parvula (max 
568 nm) were made to assess the fragments responsible for the difference in color of light 
emitted, and studies with these chimeras indicated that residues in the fragment between 
Val209 and Ala318 were responsible for the difference in the spectra between the two 
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species’ luciferases (Ohmiya et al., 1996).  Chimeric luciferases generated by Viviani and 
colleagues made up of residues 1-344 from the red light-emitting luciferase of railroad 
worm Phrixothrix hirtus (max 623 nm) and 345-545 from the green light-emitting 
luciferase of railroad worm Phrixothrix viviani (max 548 nm) showed that for these 
luciferases, only residues 1-344 were responsible for the color of light emitted (Viviani 
and Ohmiya, 2000).  
In other studies, it was shown that random and site-directed mutagenesis of a 
single amino acid in different species’ luciferases could generate proteins that emitted 
red-shifted light at pH 7.8.  Mutagenesis of Luciola cruciatai luciferase (max 562 nm) 
generated the red-shifted point mutants P452S (max 595 nm), S286N (max 607 nm), 
G326S (max 609 nm), and H433Y (max 612 nm) (Kajiyama and Nakano, 1991).  Based 
on the results Kajiyama and colleagues obtained from their random mutagenesis 
experiments, Mamaev and colleagues mutated serine 286 (Ser284 in Photinus pyralis) in 
Luciola mingrelica firefly luciferase (max 582) to a number of residues and found that all 
of these mutations red-shifted light emission: S286K max 608 nm, S286Q max 609 nm, 
S286Y max 613 nm, and S286L max 619 nm (Arslan et al., 1997; Mamaev and Laikhter, 
1996).  Random mutagenesis of Hotaria parvula luciferase also generated the point 
mutation H433Y, with max 610 nm (Ueda et al., 1996).  Furthermore, the mutation 
R215S in the green emitting railroad worm luciferase of Phrixothrix viviani was shown to 
shift its emission from 548 nm to 588 nm, but to have no effect on the light emitted from 
the red emitting luciferase of Phrixothrix hirtus (Viviani and Ohmiya, 2000).  
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In addition to random mutagenesis studies, work was also done to mutate residues 
that were conserved between the different beetle species to determine the roles played by 
different residues in color determination.  Viviani and colleagues identified residues that 
differed between the pH sensitive Photinus pyralis luciferase and the pH insensitive click 
beetle and railroad worm luciferases and performed mutagenesis studies to attempt to 
explain why certain luciferases emit longer wavelength light at acid pH and others 
emission does not change.  From this work, they found that substitution of many residues 
in the loop between residues 223-235, as well as at Ala243 (pH insensitive luciferase 
numbering) had dramatic effects on the emission properties from the various species’ 
luciferases studied (Viviani et al., 2001; Viviani et al., 2008; Viviani et al., 2002). 
It was also observed that the naturally red emitting luciferase from Phrixothrix 
hirtus possesses an arginine, R353, which is deleted in other luciferases.  Tafreshi and 
colleagues demonstrated that insertion of that corresponding residue into the luciferase 
from Lampyris turkestanicus (R356), a green emitting luciferase (max 555), generated a 
luciferase with a bimodal spectrum with an emission maximum in the red (max 615) and 
a small shoulder in the green (max 560) region (Tafreshi et al., 2007).  Additionally, this 
insertion only minimally impacted the relative activity of the luciferase. Based on this 
work, Moradi and colleagues introduced four residues at the same position in Photinus 
pyralis luciferase that were similar in size to arginine, but which had different charges 
(Arg, Lys, Glu, and Gln) (Moradi et al., 2009).  They demonstrated that while the 
insertion of a residue with a positive side chain caused a red shift in the light emitted 
(max 608), inserting a negative or neutral residue had little effect on emission. 
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Shapiro and colleagues reported on the generation of red emitting luciferases 
using error prone PCR in Photinus pyralis. Interestingly, the resulting red shifting 
mutations were all found to be located in one region of the N-terminus of luciferase 
located away from the proposed active site (Shapiro et al., 2005).  Of the mutants 
generated, the brightest and most red emitting at neutral pH were A850G/S284G (max 
603) and A848G/Q283R (max 609).   
While many studies were done to pinpoint specific residue(s) that determine the 
color emitted by luciferase, the fact that mutations at so many locations were able to red 
shift the light emitted suggested that the solution might not be so simple.  With the 
publication of the structures of firefly Photinus pyralis luciferase (Conti et al., 1996) and 
another acyl-adenylate forming enzyme, phenylalanine-activating enzyme (Conti et al., 
1997), modeling of the luciferase active site made rational site-directed mutagenesis to 
assess the structure-function basis of color determination possible (Branchini et al., 1998; 
Sandalova and Ugarova, 1999).  Based on the working model they developed, Branchini 
and colleagues performed several mutagenesis studies in Photinus pyralis luciferase of 
residues in the proposed binding site, including highly conserved residues (Branchini et 
al., 1999; Branchini et al., 1998; Branchini et al., 2001; Branchini et al., 2003).  Mutation 
of many of these residues was found to red shift the bioluminescence maximum at neutral 
pH (Table 1-1).  Further studies to better understand the adenylation and oxidation partial 
reactions in the overall production of light from firefly luciferase showed that the 
mutations K529A and K433A/K529A generated luciferase with broad red-shifted 
emission spectra (Branchini et al., 2005b).   
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Table 1-1.  Red-emitting luciferase mutants.  Mutants discovered in several 
mutagenesis screens by Branchini and colleagues (Branchini et al., 1999; Branchini et al., 
1998; Branchini et al., 2001; Branchini et al., 2003; Branchini et al., 2005b) that red shift 
light emission from firefly luciferase.  Firefly luciferase point mutants are shown in the 
left column and wavelength maxima (nm) for each mutant are shown in the right column. 
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Subsequent to the identification of many mutations that could red shift light 
emission from luciferase, efforts moved towards the generation of red shifted luciferases 
with improved properties, as often the mutations which red shift light emission also result 
in luciferases with decreased bioluminescent activity.  Based on sequence information 
from a yellow-green emitting luciferase from Pyrophorus plagiophthalamus, Almond and 
colleagues at Promega performed further mutagenesis to yield a bright thermostable red 
emitting variant (max 613) optimized for used in dual reporter assays in mammalian cells 
(Almond et al., 2003).   
Branchini and colleagues performed site directed and random mutagenesis in 
Photinus pyralis luciferase looking for a mutant that would emit red light but also 
maintain its activity, and identified the triple mutant (V241I/S284T/I351A) (Branchini et 
al., 2004a).  Further analysis showed that the S284T mutation was sufficient for the red 
light emission, narrow bandwidth and favorable kinetic properties of this mutant, and that 
it could be used in dual reporter studies with the blue-shifted luciferase mutant 
V241I/G246A/F250S (Branchini et al., 2005a).  To improve the S284T mutant further for 
imaging and reporter gene application, the mutations 
T214A/A215L/I232A/F295L/E354K were added, generating a thermostable pH 
insensitive red-emitting variant (Ppy RE-TS max 610 nm) with a narrow emission 
bandwidth (Branchini et al., 2007a).  Further mutagenesis of Ppy RE-TS red shifted the 
emission of this mutant even further, generating the mutants Ppy RE8 and Ppy RE9  (max 
617 nm) (Branchini et al., 2010a).  Ppy RE8 has been used successfully in in vivo 
bioluminescence imaging studies (Mezzanotte et al., 2011). 
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Theories of bioluminescence color determination 
Several theories have been proposed to account for the wide range of colors of 
light emitted by different luciferases.  It was originally suggested that keto-enol 
tautomerization of the oxyluciferin molecule was responsible for the different colors of 
light emitted, where the ketonic species of oxyluciferin is responsible for red light 
emission and the enolic species is responsible for yellow-green light emission (Figure 1-
2), possibly with the involvement of a basic residue in the luciferin-binding pocket 
(Viviani and Bechara, 1995; White and Branchini, 1975; White et al., 1969; White et al., 
1971; White and Roswell, 1991; White et al., 1980).  This hypothesis was supported by 
the observation that adenyl-luciferin that had undergone spontaneous oxidation in 
aqueous buffer (White et al., 1971) and an analogue of luciferin that cannot be enolized, 
5-dimethyl luciferin (White et al., 1969; White et al., 1971), both emitted red light.  
However, more recently Branchini and colleagues showed that in the presence of a 
synthetic luciferin analog (5,5-dimethyloxyluciferin) that is constrained to the keto form, 
green light is emitted by the firefly luciferase from Photinus pyralis, while red light is 
emitted by the luciferase from the click beetle Pyrophorus plagiophthalamus, suggesting 
that keto-enol tautomerization is not responsible for the observed color modulation 
(Branchini et al., 2002; Branchini et al., 2004b). 
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Figure 1-2.  Keto and enol forms of oxyluciferin.  One theory of color determination 
suggests that the keto form of the excited oxyluciferin emitter generates red light with the 
luciferase protein and that the enol form generates yellow-green light. 
 
 
In addition, Branchini and colleagues also suggested that changes in resonance-
based charge delocalization of the excited state oxyluciferin plays a role in modulating 
the color of light emitted (Branchini et al., 2002; Branchini et al., 2004b).  Specifically, 
key conserved amino acids and interactions with AMP in the luciferase-binding pocket 
play a role in controlling the charge delocalization of the anionic keto form of the excited 
oxyluciferin molecule (Figure 1-3).  An excited state species of lower energy can be 
generated by resonance stabilization of the anion and extension of the -electron 
skeleton, resulting in red light emission.  In the context of the binding pocket, specific 
amino acids and AMP minimize charge delocalization and maintain the higher energy 
anionic keto form of the excited state oxyluciferin, resulting in the emission of yellow-
green light. 
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Figure 1-3.  Resonance delocalization of excited state oxyluciferin.  One theory 
suggests that changes in resonance-based charge delocalization of the excited state 
oxyluciferin play a role in modulating the color of light emitted from luciferase. 
 
 
Based on molecular orbital calculations, McCapra and colleagues suggested that 
the conformation of the luciferin substrate in the binding pocket determines the color of 
light emitted. This theory surmises that rotation around the C2-C2’ bond of oxyluciferin 
alters the conformation of its keto emitting form and results in color variation.  
Specifically, red light emission results from the twisting of the aromatic thiazole and 
benzothiazole rings of oxyluciferin to a 90˚ angle with respect to the C2-C2’ bond, 
resulting in a minimum energy conformation termed a twisted intramolecular charge 
transfer (TICT) excited state (Figure 1-4).  Yellow-green light is emitted by the higher 
energy excited state oxyluciferin where the molecule is held planar and bond rotation is 
prevented (McCapra, 1997; McCapra et al., 1994).  This has since been refuted by 
multiple studies (Nakatani et al., 2007; Nakatsu et al., 2006; Orlova et al., 2003; Yang 
and Goddard, 2007). 
 
 16 
   
 
Figure 1-4. Twisted intramolecular charge transfer (TICT) excited state.  Rotation 
around the C2-C2’ bond, where the aromatic thiazole and benzothiazole rings of 
oxyluciferin are at a 90˚ angle with respect to the C2-C2’ bond, generates the minimum 
energy conformation, and red emitting species, of excited state oxyluciferin. 
 
 
One of these refuting theories sites the rigidity of the active site in determining the 
color of light emitted.  This hypothesis is based on crystallography studies of a WT and a 
red-shifted mutant (S286N) (Kajiyama and Nakano, 1991) of Japanese Genji-botaru 
(Luciola cruciata) luciferase in complex with a high-energy intermediate analog 5’-O-[N-
(dehydroluciferyl)-sulfamoyl]adenosine, DLSA.  As compared to structures of WT 
protein in complex with the reaction products oxyluciferin and AMP, a conformational 
change is observed in the WT protein complexed with DLSA, but not the red shifted 
mutant.  This conformational change involves the movement of a hydrophobic residue 
(Ile288) closer to the benzothiazole ring of the substrate, resulting in a “closed” form, 
while the S286N mutant maintains an “open” form like that seen with the WT protein and 
the reaction products oxyluciferin and AMP.  Nakatsu and colleagues suggest that the 
conformational changes that occur in the WT enzyme during catalysis generate a very 
hydrophobic, rigid environment in the active site, which minimizes energy loss resulting 
it the emission of high-energy yellow green light.  They also hypothesize that because 
S286N remains in the “open” form, the active site is less hydrophobic and less rigid and 
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energy loss can occur during catalysis, potentially through reorganization or thermal 
relaxation, resulting in the emission of lower energy longer wavelength red light 
(Nakatsu et al., 2006).  Also, in the crystal structure of both WT and S286N in complex 
with the luciferyl adenylate intermediate analogue, the benzothiazole and thiazole rings 
of the molecule are almost coplanar.  Nakatsu and colleague argue that this refutes the 
hypothesis of C2-C2’ bond rotation as a key factor in color determination. 
Computational studies using high density functional theory, where neutral and 
anionic forms of both the parent luciferin and of the keto- and enol- derivatives of 
oxyluciferin were examined, also suggest that the C2-C2’ bond rotation hypothesis is 
unlikely (Orlova et al., 2003).  The length of the C2-C2’ bond predicted in these studies 
reflects the conjugation across it and would make rotation about the bond difficult.  
Orlova and colleagues suggest that the specific method used by another group who 
claimed to verify the twisted keto-form (Stewart, 1999) does not fully appreciate the 
nature of conjugated single bonds (Cramer, 2002; Jensen, 1999).  Instead, they attribute 
the polarity of the excited oxyluciferin molecule in the context of the environment of the 
binding pocket of luciferase as key in color determination.  Specifically, they postulate 
that differences in the strength of amino acid interactions with terminal H-O groups on 
oxyluciferin can alter the color from either the keto or the enol form of the molecule, 
allowing for a range of colors of light to be emitted. 
 In fact, many groups have cited polarity as the key factor in determining the color 
of light emitted, where the higher the polarizability, the larger the red shift in 
bioluminescence (Gandelman et al., 1993). For example, it has been shown that the 
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introduction of residues that increase polarizability of the emitter sites correlates with a 
red shift in light emitted (Ugarova and Brovko, 2002) and that the introduction of 
residues that decrease polarity of the emitter site can blue shift light (Branchini et al., 
2007b).  
In efforts to generate a sensor for cyclic AMP-dependent protein kinase 
phosphorylation events, Sala-Newby and colleagues mutated residue Val217 to the basic 
residue Arg in Photinus pyralis luciferase, creating the phosphorylation site RRFS.  They 
found that while the V217R mutant exhibited a green shifted emission profile with 
respect to the native protein, phosphorylation of the V217R mutant by the catalytic 
subunit of protein kinase A mutant induced a red-shift in the light emitted (Sala-Newby 
and Campbell, 1991).  Also, fluorescence studies with 8-anilinio-1-napthene sulfonic acid 
and 6-p-toluidino-2-napthene sulfonic acid showed that in the naturally occurring red 
light emitting luciferase from Phrixothrix hirtus, the luciferin binding pocket is more 
polar than that of green light emitting Phrixothrix viviani’s luciferase (Ugarova and 
Brovko, 2002; Viviani et al., 2006; Viviani and Ohmiya, 2006).   
In addition to the work done by Orlova and colleagues, many other theoretical 
studies point to polarity as the main factor determining the color of light emitted by 
luciferase (Hirano et al., 2009; Liu et al., 2008; Nakatani et al., 2007; Navizet et al., 2010; 
Orlova et al., 2003; Silva and Da Silva, 2011).  Hirano and colleagues performed a 
thorough examination of the spectroscopic properties of the phenolate anion generated 
from 5,5-dimethyloxyluciferin, which was intended to represent the keto form of the 
oxyluciferin phenolate anion, in different solvents with added organic base.  Based on 
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this, they suggested that in addition to the polarity of the luciferin binding pocket, the 
strength of the covalent nature of a hydrogen bond of the phenolate oxygen of the keto 
form of the oxyluciferin phenolate anion with a protonated basic moiety in the active site 
is a main factor in color determination (Hirano et al., 2009).   
Several of the theoretical studies also claim to disprove one or more of the 
theories of color determination. Nakatani and colleagues used quantum and molecular 
mechanical calculations as well as the symmetry-adapted cluster/symmetry-adapted 
cluster−configuration interaction method in combination with crystallography data (Conti 
et al., 1996) and models established in other experimental studies (Branchini et al., 1999; 
Branchini et al., 1998; Branchini et al., 2001) to analyze the factors that contribute to 
color determination in firefly luciferase (Nakatani et al., 2007). They claim that their 
studies refute many of the proposed theories on color determination.  Like other groups, 
they claim that twisting about the C2-C2’ bond is unlikely to be a factor in color 
determination as the TICT state can easily relax to a coplanar state.  Also, while they 
observe that emission energy of the enol form of oxyluciferin is similar to that of the keto 
form, they claim that the transition from keto to enol would be unlikely based on the 
energetic instability of the enol form in the context of the luciferase binding pocket. 
Additionally, they claim that while the protonation state of the 6’ oxygen of oxyluciferin 
contributes to color determination, based on their studies it would not be energetically 
favorable for the protonation to involve a transfer from residue Arg218 to the keto form 
of oxyluciferin, as had been postulated.  Finally, they claim that based on their 
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calculations regarding the ground and excited state resonance structures of oxyluciferin, 
the excited state structures would be insensitive to the local environment. 
Navizet and colleagues examined the “open” and “closed” X-ray structures of 
Luciola cruciata luciferase (Nakatsu et al., 2006) to determine the mechanism of firefly 
color determination using a multiconfigurational reference second-order perturbation 
theory-molecular mechanics study for the first time (Navizet et al., 2010).   From these 
studies, they claim that the different sizes of the luciferin binding pocket in the “open” 
and “closed” forms does not impact the relative structures of the oxyluciferin substrate 
enough to cause the change in color observed, refuting Nakatsu and colleagues 
hypothesis regarding the mechanism of color determination.   
Oxyluciferin is usually thought to be able to exist as one of six chemical forms 
(Figure 1-5).  In general, there continues to be an ongoing debate regarding the species of 
the emitter and spectral determination. While from 1971-2002 it was generally thought 
that both the keto and enol/enolate forms of oxyluciferin were the light emitters (Ugarova 
and Brovko, 2002; White and Branchini, 1975; White et al., 1971; White and Roswell, 
1991; White et al., 1980), from 2002-2009 the keto form of the oxyluciferin phenolate 
anion was generally considered the light emitter in the context of the firefly (Branchini et 
al., 2002; Branchini et al., 2004b; Hirano et al., 2009; Liu et al., 2008; Nakatani et al., 
2007; Navizet et al., 2010).   
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Figure 1-5.  Structures of the emitter.  The six different potential forms of the excited 
state oxyluciferin emitter. 
 
 
However, based on NMR and fluorescence spectra of oxyluciferin and its 5-
methyl analog, Nuamov and colleagues suggested that the enol form of excited state 
oxyluciferin can also play a role in emission and additionally that it is a culmination of 
the effects of pH, active site polarity, the presence of ionic species in the binding pocket, 
and  stacking that ultimately determine the color of light emitted (Naumov et al., 
2009).  They later did similar studies using a 6’ dehydroxylated derivative of oxyluciferin 
to determine the spectra-structural effects of the equilibrium between the keto-enol-
enolate and phenol-phenolate forms of oxyluciferin and claim that the phenol-enolate 
form of excited state oxyluciferin is a yellow emitter (Naumov and Kochunnoonny, 
2010).  Other recent studies suggest that the phenolate-keto oxyluciferin, but not 
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phenolate-enol oxyluciferin, is the yellow-green emitter (Min et al., 2010a), that the 
phenolate-keto oxyluciferin is both the yellow-green and red emitter (da Silva and 
daSilva, 2011; Milne et al., 2010), and that the phenolate-keto oxyluciferin is the only 
emitter in natural firefly bioluminescence (Chen et al., 2011).  Additionally, Min and 
colleagues even suggested that a seventh species of oxyluciferin is formed when the 
anionic keto form is protonated on the oxygen of the thiazole ring (Figure 1-6), and this 
species could be the red emitter (Min et al., 2010b). Navizet and colleagues (Navizet et 
al., 2010) claim that because many of the theoretical methods used to investigate the 
emission spectra of oxyluciferin are done in vacuo and at the density function level of 
theory, they may fail to correctly account for contributions from residues in the binding 
pocket during the reaction and may not properly consider the charge-transfer states.  The 
degree to which these different factors are considered may in part explain the 
discrepancies between the different conclusions made from theoretical studies. 
Undoubtedly, debate on this topic will continue. 
 
 
 
Figure 1-6.  Seventh proposed structure of the oxyluciferin emitter.  Proposed 
structure of the red emitting species of excited state oxyluciferin where the thiazole 
oxygen is protonated. 
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BRET as a method to generate red-emitting luciferases 
An alternative method that has been used to generate red-emitting luciferases 
takes advantage of BRET. Aria and colleagues used the firefly Hotaria parvula luciferase 
tagged with GST and Discosoma red fluorescent protein (DsRed) tagged with protein G 
as a red emitting BRET pair, brought together by the addition of an anti-GST antibody 
(Arai et al., 2002).   Another group modified the blue emitting “sea firefly” Cypridina 
luciferase with a far-red fluorescent indocyanine derivative to generate a BRET pair that 
would produce far-red luminescence (Wu et al., 2009a). Similarly, Branchini and 
colleagues generated a red emitting Photinus pyralis mutant Ppy RE8 with two surface 
exposed cysteines that could be modified with Alexa Fluor near infrared (nIR) dyes, 
allowing BRET to occur and resulting in nIR light emission (Branchini et al., 2010b).  
They went on to use a similar approach to generate a fusion of RFP and a thermostable 
Photinus pyralis luciferase variant (Branchini et al., 2011).  Modification of the RFP with 
nIR Alexa Fluor dye allowed for sequential BRET-FRET energy transfer, resulting in 
nIR light emission.  
Other groups coupled quantum dots to a mutant of Renilla reniformis luciferase to 
produce a BRET pair that emits light in the red to far-red region (Ma et al., 2010; So et 
al., 2006). More recently, Dragulescu-Andrasi and colleagues fused a variant of Renilla 
luciferase to FKBP12 rapamycin binding domain (FRB) and two different RFPs to 
rapamycin-induced FK506 binding protein 12 (FKBP12).  In the presence of the Renilla 
substrate coelenterazine and rapamycin, which brings the FRB and FKBP12 together, 
BRET occurs, resulting in the emission of red light. (Dragulescu-Andrasi et al., 2011)  
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However, approaches like these that use the Renilla luciferase suffer from the same 
limitations intrinsic to the coelenterazine substrate mentioned above. 
Rather than modifying the luciferase protein itself, another group modified the 
luciferin substrate instead.  Specifically, Takakura and colleagues modified a luciferin 
analog with Cy5, a nIR cyanine fluorescent dye.  BRET between Cy5 and the luciferin 
analog results in nIR light emission when reacted with firefly luciferase (Takakura et al., 
2011). 
 
Novel luciferin substrates 
While much work has been done to characterize native red-emitting luciferases, 
create luciferases that emit red light, and define the factors that cause color change, since 
the late 1960’s, less has been done to generate novel luciferin substrates. One of the first 
reported analogs of D-luciferin to interact with firefly luciferase to produce light was 
aminoluciferin (6’-NH2LH2), where an electron-donating amino group replaced the 6’ 
hydroxyl normally found on luciferin (White et al., 1966).  This novel luciferin substrate 
red shifted the light emitted from firefly luciferase (max 605) and unlike D-luciferin, this 
shift was independent of pH. However when the 6′-hydroxyl of luciferin is removed, or 
replaced with 6′-methoxy, ethoxy, or N-acetylamino groups, although the luciferase 
proteins still bind the luciferins despite the bulky additions, no light is emitted (Denburg 
and McElroy, 1970).  White and colleagues also generated three hydroxy positional 
isomers of luciferin and a di-hydroxy analog, 4-hydroxyluciferin.  Of these, only 4-
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hydroxyluciferin was positive for light emission with luciferase, and the light emitted 
with this analog was also red (White and Worther, 1966). 
More recent work has included the generation of a non-benzothiazole 
bioluminescent substrate for firefly luciferase, D-quinolylluciferin, which shifted the 
wavelength of light emitted to the red (max 608 nm) (Branchini, 2000; Branchini et al., 
1989).  Like 6-NH2LH2, the red shift observed with D-quinolylluciferin was independent 
of pH.  Takakura and colleagues made quinolyldimethylaminoluciferin that emits light at 
max 601 nm with firefly luciferase (Takakura et al., 2010). 
 Recently, our group generated novel synthetic alkylamino luciferin analogs that 
result in the emission of red-shifted light from WT firefly luciferase by replacing the 6’ 
phenolic hydroxyl of D-luciferin with electron-donating acyclic monomethyl and 
dimethyl alkylamino groups, as well as cyclic alkylamino groups (Figure 1-7) (Reddy et 
al., 2010).  When tested with WT luciferase, these synthetic aminoluciferin substrates 
shifted the emission wavelength of emitted light to varying degrees (Table 1-2), with 6’-
Me2NLH2 shifting the emission wavelength most toward the red at 623 nm.  CycLuc1 
and CycLuc2 exhibited superior light output and were shown to be more efficient light 
emitters than their respective acyclic counterparts.  This is likely because the acyclic 
aminoluciferins possess a reduced quantum yield in relation to cyclic substrates.  In the 
acyclic aminoluciferins, there is the potential for poor overlap of the lone pair of nitrogen 
with the conjugation of the rest of the luciferin as a result of free rotation around the aryl-
nitrogen bond, particularly in the context of the binding pocket where molecular 
interactions between the enzyme and substrate might stabilize such a conformer.  This 
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likely reduces the quantum yields of these substrates.  Cyclic aminoluciferins, on the 
other hand, likely have a relatively higher quantum yield because they are 
conformationally rigid and possess reduced bond rotation as a result of the cyclization. 
 
 
  
 
Figure 1-7. Luciferin substrates.  D-luciferin, aminoluciferin, and four novel acyclic 
and cyclic alkylamino luciferin molecules that, with the luciferase protein, generate red 
light (Reddy et al., 2010). 
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Table 1-2.  max with novel luciferins and WT luciferase.  Wavelength maxima values 
(nm) with WT luciferase and D-luciferin, aminoluciferin and novel aminoluciferin 
substrates (Reddy et al., 2010). 
 
 
 While the alkylamino substrates exhibited a red shift in the light emitted from WT 
luciferase relative to D-luciferin, a significant reduction in the overall light output for the 
aminoluciferins relative to D-luciferin was also observed.  Rapid-injection (Branchini et 
al., 1998) of the luciferase protein into buffer containing the luciferin analogs revealed an 
initial burst of light, followed by reduced sustained light output for all of the alkylamino 
substrates tested.  This indicates that while these synthetic luciferins can be rapidly 
converted to light-emitting oxyluciferin, they are subsequently subject to product 
inhibition, due to the high affinity of the reacted non-light producing product.  The burst 
kinetic behavior of even WT firefly luciferase and D-luciferin is well-known (Fraga, 
2008).   
Ultra-Glo, a highly mutated luciferase from Promega, has been shown to be 
resistant to inhibition during high-throughput screening assays (Auld et al., 2009; Hall et 
al., 1998) and by substrates known to inhibit WT luciferase, particularly in the presence 
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of P450-Glo buffer (Woodroofe et al., 2008).  Similarly, Ultra-Glo luciferase in P450-Glo 
buffer is able to effectively utilize our novel alkylamino luciferin substrates, relieving the 
burst kinetic profiles observed with the WT protein.  However, Ultra-Glo is not available 
as a genetic construct and in many applications, requires the P450-Glo buffer to exhibit 
sustained light output (Prescher and Contag; Shinde et al., 2006).  Efforts toward the 
generation of luciferase mutants that are able to produce sustained light emission without 
product inhibition with our novel alkyl aminoluciferins, which can also function under 
physiological conditions, will prove advantageous for studies within cells and whole 
organisms. 
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CHAPTER II: Identification of mutant firefly luciferases that efficiently utilize 
aminoluciferins 
Summary 
Firefly luciferase-catalyzed light emission from D-luciferin is widely used as a 
reporter of gene expression and enzymatic activity both in vitro and in vivo. Despite the 
power of bioluminescence for imaging and drug discovery, light emission from firefly 
luciferase is fundamentally limited by the physical properties of the D-luciferin substrate. 
We and others have synthesized aminoluciferin analogs that exhibit light emission at 
longer wavelengths than D-luciferin and have increased affinity for luciferase. However, 
although these substrates can emit an intense initial burst of light that approaches that of 
D-luciferin, this is followed by much lower levels of sustained light output. We have 
previously postulated that this behavior is due to product inhibition. Here we describe the 
creation of mutant luciferases that yield improved sustained light emission with 
aminoluciferins in both lysed and live mammalian cells, allowing the use of 
aminoluciferins for cell-based bioluminescence experiments. 
 
Introduction 
 Light emission from firefly luciferase is fundamentally limited by its access to D-
luciferin and the inherent photophysical properties of the D-luciferin substrate (Figure 1-
1) (Reddy et al., 2010).  Replacement of the 6’-hydroxyl group of D-luciferin with a 6’-
amino group results in red-shifted light emission (White et al., 1966) and higher affinity 
for luciferase, but lower maximal light emission and lower cell-permeability (Shinde et 
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al., 2006). Although D-luciferin is the superior substrate for maximal light emission 
under most conditions, the unique chemistry of 6’-aminoluciferin has expanded the scope 
of luciferase applications. For example, the liberation of 6’-aminoluciferin from “dark” 
pro-luciferin protease substrates has been exploited to allow the coupled bioluminescent 
detection of protease activity, both in vitro (Monsees et al., 1994; Moravec et al., 2009) 
and in vivo (Shah et al., 2005; Dragulescu-Andrasi et al., 2009; Hickson et al., 2010; 
Scabini et al., 2011).  
Recently, we and others have reported that 6’-alkylaminoluciferins can also be 
substrates for luciferase (Woodroofe et al., 2008; Reddy et al., 2010; Takakura et al., 
2010). These substrates generally have even higher affinity for luciferase than 6’-
aminoluciferin, and emit light at even longer wavelengths. Many modifications are 
tolerated, including long-chain 6’-alkylaminoluciferins, 5’,6’-cyclic alkylaminoluciferins, 
and even dialkylaminoluciferins (Figure 1-7). Synthetic modulation of the properties of 
these molecules thus presents an opportunity to develop new bioluminescent probes and 
to optimize luciferase light output for different applications. However, with wild-type 
Photinus pyralis firefly luciferase, most of these substrates give a rapid burst of light 
followed by weak sustained emission (Reddy et al., 2010). 
The detergent-stable proprietary mutant luciferase Ultra-Glo (Promega) is capable 
of high sustained light emission with aminoluciferin substrates, particularly in 
combination with the P450-Glo buffer (Woodroofe et al., 2008; Reddy et al., 2010). The 
use of aminoluciferins with this luciferase and buffer therefore has potential for novel in 
vitro screening applications, such as the coupled detection of enzymatic activity (Fan and 
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Wood, 2007).  However, Ultra-Glo is a proprietary luciferase reagent that is not available 
as a genetic construct that can be expressed in cells. Furthermore, the detergent stability 
of Ultra-Glo and the use of the P450-Glo buffer are important for the light emission 
behavior. Cellular and in vivo applications such as the detection of gene expression (de 
Wet et al., 1987) and bioluminescent imaging (Prescher and Contag, 2010) necessitate a 
genetically-encodable luciferase that is capable of efficient utilization of aminoluciferins 
under physiological buffer conditions. 
We postulated that aminoluciferin substrates possess all of the key photophysical 
and structural features necessary to give rise to bioluminescence, but are primarily 
limited as luciferase substrates due to product inhibition (Reddy et al., 2010). Here we 
report the construction of mutant luciferases capable of sustained and selective light 
emission with aminoluciferins, thereby expanding the available tools for bioluminescence 
imaging. 
 
Materials and Methods 
Materials 
Chemicals for synthesis were from Aldrich unless otherwise noted. Data was 
plotted with GraphPad Prism 5.0.  NMR spectra were recorded on a Varian Mercury 400 
MHz NMR. Small molecule mass spectral data were recorded on a Waters QTOF 
Premier. Protein structures were displayed with ICM-Browser (MolSoft).  
Bioluminescence measurements were taken in a Turner Veritas luminometer and were 
not corrected for differences in the wavelength sensitivity of the PMT.  Emission spectra 
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and burst kinetic data measurements were recorded on a Spex FluoroMax-3 fluorimeter.  
D-Luciferin was from Anaspec and 6’-aminoluciferin was from Marker Gene 
Technologies Inc.  CycLuc1, CycLuc2, 6’-MeNH-LH2, and 6’-Me2NLH2 were 
synthesized as previously described (Reddy et al., 2010). Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). Immobilized glutathione (Thermo 
Scientific) was used for GST-tagged protein purification. Unless otherwise stated, all 
protein purification steps were carried out at 4˚C.  
 
Plasmid constructs 
The Photinus pyralis firefly luciferase gene was PCR-amplified from pGL3 
(Promega) and cloned into the BamHI and NotI sites of pGEX6P-1 for bacterial 
expression.  Mutant proteins were created using the Quickchange site-directed 
mutagenesis kit (Stratagene).  Saturating mutagenesis was performed at sites predicted to 
impact or alter substrate binding, including: F247, T251, L286, S347, R337, R218, Y340, 
and I351, using the degenerate codon NNK.  The point mutants S347A, L286A, A348G, 
E311A, I351A, and R337A were made independently. 
 
Mutant screening 
Screening for mutant luciferases was performed in the E. coli strain JM109, which 
has high transformation efficiency and plasmid recovery, as well as reasonable levels of 
inducible protein expression. Other bacterial strains (OMNI, DH5a, BL21(DE3), 
XL1Blue, XL10Gold), gave less consistent results. Following saturating mutagenesis, 
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500 L of the E. coli strain JM109 was transformed and plated on 5 Luria-Bertani (LB) 
plates that contained 50 mg/mL carbenicillin. Colonies were picked and used to inoculate 
two 96-well plates where each well contained 150 L of LB with 50 mg/mL 
carbenicillin.  Inoculated plates were incubated at 37 ˚C overnight.  Cells were induced 
with 0.1 mM isopropyl--D-thiogalactopyranoside (IPTG) and incubated at RT 
overnight.  Five L of the bacterial protein extraction reagent SoluLyse (Genlantis) was 
then added to 50 L of induced cells followed by a 10-minute incubation at RT.  Two L 
of lysate was then added to 60 L of a solution containing 25 M substrate in 20 mM 
Tris pH 7.6, 0.1 mM EDTA, 8 mM MgSO4, 4 mM ATP, and 1 mM TCEP in each well of 
a white 96-well plate (Costar 3912). The bioluminescence emission was measured in a 
Turner Veritas luminometer after a delay of 2-5 minutes.  Readings were taken every 30 
seconds for a total of 10 runs.  Mutants that displayed desired emission profiles with the 
different substrates tested at 25 M were then used in titration assays at substrate 
concentrations ranging from 0.122-250 M.   Mutants of interest were then sequenced, 
expressed, and purified for further characterization.   
 
Protein expression 
Mutant luciferases were expressed as GST-fusion proteins from the vector 
pGEX6P-1 in the E. coli strain JM109.  Cells were grown at 37 ˚C until the OD600 
reached 0.5-1, induced with 0.1 mM IPTG, and incubated at 20 ˚C overnight.  Cells were 
pelleted at 5000 rpm in a Sorvall 2C3C Plus centrifuge (H600A rotor) at 4˚C for 10 
minutes, then flash-frozen in liquid nitrogen and purified immediately or stored at -80 ˚C. 
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Luciferase purification 
E. coli cell pellets from one liter of culture were thawed on ice, resuspended in 25 
mL Lysis Buffer (50 mM HEPES pH 7.4, 500 mM NaCl, and 0.5% Tween-20) 
containing 1 mM PMSF, and disrupted by sonification (Branson Sonifier).  Dithiothreitol 
(DTT) was added at 10 mM and the resulting cell lysate was clarified by centrifugation at 
35K rpm in a Beckman 50.2Ti rotor for 30-45 minutes.  The supernatant was batch-
bound to immobilized glutathione for 1h at 4˚C, and the beads were washed with Lysis 
Buffer containing 10 mM DTT, followed by Wash Buffer (50 mM Tris pH 8.1, 250 mM 
NaCl and 10 mM DTT), and finally with Storage Buffer (50 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM TCEP).  Twenty units of PreScission Protease (GE Healthcare) were added 
and incubation continued for 4 hours or overnight at 4˚C to cleave the GST-fusion and 
elute the untagged luciferase protein. 
 
Substrate titration assays with purified protein 
Luminescence assays were initiated by adding 30 L 2x substrate in either buffer 
A (20 mM Tris pH 7.6, 0.1 mM EDTA, 8 mM MgSO4, 4 mM ATP, and 1 mM TCEP) or 
buffer B (20 mM Tris pH 7.6, 0.1 mM EDTA, 8 mM MgSO4, 4 mM ATP, 6 mg/mL 
BSA, and 33 mM DTT) to 30 L of 20 nM purified luciferase in 20 mM Tris pH 7.6, 0.1 
mM EDTA, 1 mM TCEP and 0.4 mg/mL BSA in a white 96-well plate (Costar 3912). 
Substrate titration assays were performed 3 minutes post-substrate addition in a Turner 
Veritas luminometer with final substrate concentrations ranging from 0.122-125 M. 
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Cell Culture 
Chinese hamster ovary-K1 (CHO-K1) cells were grown in a CO2 incubator at 
37˚C with 5% CO2 and were cultured in F-12K Nutrient mixture (GIBCO) supplemented 
with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. 
 
Transfections 
Mutant luciferases F247A, F247L, F247V, F247S, T251S, L286M, S347A, 
S347T, and R218K were cloned into the BamHI-NotI site of pcDNA 3.1 and transfected 
into CHO-K1 cells for live and lysed cell experiments.  Transient transfections were 
performed at room temperature using Lipofectamine 2000 on cells plated at 60-75% 
confluency in 96-well white tissue culture treated plates (Costar 3917) for intact cell 
assays, or 6-well plates for lysed cell assays.  For intact cells, 0.075 g DNA/well was 
transfected and for lysed cells, 2.25 g DNA/well was transfected.  Assays were 
performed in triplicate 24 hours post-transfection. 
 
Intact Cell Assays 
Transfected CHO cells were washed with HBSS and overlaid with 60 L 
substrate in HBSS. Titration assays were performed 3 minutes post-substrate addition in a 
Turner Veritas luminometer with final substrate concentrations ranging from 0.122-125 
M. 
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Lysed Cell Assays 
Transfected CHO cells were washed with HBSS and lysed for 10 minutes at RT 
with 1 mL 1x Passive Lysis Buffer (Promega) per well.  Cells from one and a half wells 
of a 6-well plate were used to test one substrate in triplicate at the 12 concentrations 
tested.  Luminescence assays were initiated by adding 30 L 2x substrate in 20 mM Tris 
pH 7.6, 0.1 mM EDTA, 8 mM MgSO4, 4 mM ATP, 6 mg/mL BSA, and 33 mM DTT to 
30 L of lysate in a white 96-well plate (Costar 3912). Titration assays were performed 3 
minutes post-substrate addition in a Turner Veritas luminometer with final substrate 
concentrations ranging from 0.122-125 M. 
 
Bioluminescence Emission Scans and Burst Kinetics Assays 
Each purified protein in 20 mM Tris pH 7.6, 0.1 mM EDTA, 1 mM TCEP and 0.4 
mg/mL BSA was added to 2x substrate in 20 mM Tris pH 7.6, 0.1 mM EDTA, 8 mM 
MgSO4, 4 mM ATP, and 1 mM TCEP in a cuvette.  Final protein concentrations were 10 
nM and substrate concentrations were 10 M. 
 
Bioluminescence Emission Scans 
Luciferase was rapidly injected into a cuvette containing substrate, and the 
emission from 400-800 nm was recorded in a SPEX FluoroMax-3 fluorimeter with closed 
excitation slits 10 seconds post-injection. 
 
Burst Kinetics Assays 
 37 
Measurements were taken in a Spex FluoroMax-3 fluorimeter every second with a 
0.1 second integration time at the maximal emission wavelength for each 
luciferase/substrate pair.  Ten seconds after beginning the assay, protein was rapidly 
injected into the cuvette containing substrate to observe both the burst and the steady-
state light emission over the first minute. 
 
Results 
Rational mutation of luciferase 
 Our initial efforts to improve luciferase light emission with alkylaminoluciferin 
substrates focused on rational mutation of phenylalanine 247 in the luciferin binding 
pocket. This residue is involved in a -stacking interaction with D-luciferin (Branchini et 
al., 2003; Nakatsu et al., 2006). Mutation of this residue to leucine and alanine has been 
previously reported by Branchini et al., who found that F247L lowers the affinity for D-
luciferin but does not impair catalysis, while F247A is severely impaired in both Km and 
Vmax (Branchini et al., 2003). We therefore anticipated that F247L would maintain 
catalytic function but allow improved product dissociation, helping to relieve product 
inhibition and allowing improvement in the sustained light emission from 
alkylaminoluciferin substrates.  
Surprisingly, we found that the F247L mutation improves maximal light emission 
from 6’-aminoluciferin by 4.9-fold but has only a small positive effect on light emission 
from CycLuc1 (Figure 2-1; Figure 2-2). Instead, we found that the F247A mutation, 
which has a marked negative effect on light output from both D-luciferin and 6’-
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aminoluciferin, gave dramatically improved sustained light output from CycLuc1 (Figure 
2-1; Figure 2-2). The improved light output of this mutant comes at the cost of a 
substantially increased Km value.  While this is not a concern under conditions where 
saturating concentrations of substrate can be applied (e.g., in vitro), a high Km is expected 
to limit light output in live cells (Figure 2-2), where only low intracellular concentrations 
of luciferin substrates are achieved (de Wet et al., 1987; Craig et al., 1991; Shinde et al., 
2006). We therefore sought alternate sites for mutation that could potentially increase 
light output yet retain a low Km. 
 
 39 
 
 
 
Figure 2-1. Preliminary characterization of phenylalanine 247 mutants. Dose-
response curves for purified luciferases (WT, F247L, F247A, F247S, and F247V) were 
generated with D-Luciferin, 6’-NH2LH2 and CycLuc1 at concentrations from 0.122-125 
M. The assays were performed in triplicate and are represented as the mean ± SEM. 
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Figure 2-2. Dose-response profiles from purified luciferases and luciferases 
transfected into CHO-K1 cell lysate and in live cells. Titration assays with the native 
substrate D-Luciferin, 6’-NH2LH2 and CycLuc1 were performed at concentrations from 
0.122-125 M.  (A) Titration assays performed using 10 nM purified WT, F247L, 
F247A, F247S, or F247V firefly luciferase.  (B and C) CHO-K1 cells transiently 
transfected with pcDNA3.1 vectors expressing WT, F247L, F247A, F247S, or F247V 
firefly luciferase using lysates from the transfected cells (B) or using the intact live cells 
(C). The assays were performed in triplicate and are represented as the mean ± SEM. 
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Screening for Mutant Luciferases with Improved Utilization of Aminoluciferins 
Because mutation of phenylalanine 247 was found to affect substrate utilization, 
but not in an easily predictable manner, we opted to perform saturating mutagenesis at 
this and other active site residues, and then screen for mutant luciferases with the desired 
properties. This approach has the advantage of rational site selection, but is not restricted 
by preconceived notions of suitable replacement residues. Based on the crystal structure 
of Luciola cruciata luciferase (Nakatsu et al., 2006), we identified a number of amino 
acids that appear to interact with D-luciferin, ATP, or that play a role in creating the 
overall local structure of the binding pocket (Figure 2-3A; Table 2-1).  In addition to 
phenylalanine 247, we selected arginine 218, threonine 251, leucine 286, tyrosine 340, 
and serine 347 for saturating mutagenesis. Arginine 218 is proximal to the 4’- and 5’-
carbons of D-luciferin and forms part of the van der Waals surface that encompasses the 
luciferin substrate (Nakatsu et al., 2006). Mutations at this site were expected to provide 
increased “wiggle room” for substrates, particularly those with 5’-modifications (i.e., 
CycLuc1 and CycLuc2). Leucine 286 is a candidate residue for interaction with alkyl side 
chains on aminoluciferin substrates, while tyrosine 340 forms part of the ATP binding 
site and is located at the interface between the ATP and luciferin binding pockets. The 
methyl group of the threonine 251 side chain makes a van der Waals interaction with the 
benzothiazole of the luciferin substrate, while serine 347 forms a hydrogen bond to the 
benzothiazole nitrogen through the intermediacy of a water molecule (Nakatsu et al., 
2006). We reasoned that mutation at these sites could potentially lead to improved 
continuous light emission from aminoluciferins by altering substrate alignment and/or 
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improving product dissociation. Because aminoluciferins have higher affinity for 
luciferase, the loss of interactions with the benzothiazole could also confer selectivity 
over D-luciferin, particularly if the affinity and proper orientation of alkylaminoluciferins 
can be maintained by ancillary interactions that are not available to D-luciferin. 
 
 
 
Figure 2-3. Creation of mutant luciferases.  (A) Mutation sites were selected based on 
proximity to the luciferin substrate in the crystal structure of Luciola cruciata luciferase 
(PDB 2D1R). (B) Selected residues were subjected to saturating mutagenesis. Mutant 
luciferase-expressing bacteria were screened for light emission with CycLuc1 and those 
that exhibited improved properties were sequenced (Table 2-1) and the mutant protein 
was purified for further characterization. 
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Table 2-1.  Mutants identified in saturating mutagenesis screen. Mutation sites were 
selected based on proximity to the luciferin substrate in the crystal structure of Luciola 
cruciata luciferase (PDB 2D1R). Selected residues were subjected to saturating 
mutagenesis (Figure 2-3). Mutant luciferase-expressing bacteria were screened for light 
emission with CycLuc1 and those that exhibited improved properties were sequenced. 
 
 
At each selected site, we used the degenerate codon NNK to perform saturating 
site-directed mutagenesis in the wild-type Photinus pyralis luciferase (Figure 2-3B). At 
some sites we also introduced alanine point mutations (see Methods). After cloning of the 
mutant luciferases into bacteria, colonies were picked and grown in 96-well plates 
(Figure 2-3B). Luciferase expression was induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG) and the bacteria were lysed. Light emission from each 
lysate was measured at a luciferin concentration of 25 M.  For those lysates that gave 
improved and/or selective light output with CycLuc1, the plasmid encoding the mutant 
luciferase was sequenced (Table 2-1). Mutation at some sites failed to produce any 
obvious improvement in luciferase performance. For example, mutation of tyrosine 340 
in the nucleotide binding pocket primarily yielded inactive luciferases. In hindsight, 
Y340 makes a hydrogen-bonding interaction with D420 that may be critical for luciferase 
function (Nakatsu et al., 2006). A secondary assay was also performed on the bacterial 
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extracts to measure light output as a function of CycLuc1 concentration (Figure 2-3B).  
Mutants that demonstrated improved light output, low Km, and/or selectivity for CycLuc1 
in this assay were expressed as recombinant proteins and purified for further 
characterization.  
 
Characterization of Mutant Luciferases In Vitro 
Screening for mutants of phenylalanine 247 identified F247S and F247V as 
proteins with greatly improved light output from CycLuc1, but still with relatively high 
Km values (Figure 2-1).  Mutations at several of the other chosen sites (R218K, T251S, 
L286M, S347T, and S347A) improved light emission with aminoluciferins, while 
retaining Km values below that of the native substrate D-luciferin. For these purified 
mutant luciferases, light output as a function of substrate concentration was measured 
with D-luciferin and the aminoluciferin substrates shown in Figure 1-7, with nonlinear 
regression fitting to the Michaelis-Menten equation (Figure 2-4; Table 2-2).  For most of 
the luciferase mutants, the rank of light output was D-Luciferin > CycLuc1 > 6’-NH2LH2 
> 6’-MeNHLH2 > CycLuc2 > 6’-Me2NLH2.  In all cases, the aminoluciferins exhibited 
much lower Km values than D-luciferin. The R218K mutant was the most generally 
beneficial mutation, yielding the greatest light output for most aminoluciferin substrates, 
including a 20-fold improvement in the maximal sustained emission from CycLuc2 while 
retaining a very low Km of 0.3 M (Figure 2-4; Table 2-2).  Similarly, the maximal 
sustained light emission from CycLuc1 was increased 14-fold to 12.5% of that of D-
luciferin with WT luciferase, with a Km of 1.8 M that is still substantially lower than 
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that of D-luciferin. The R218K mutation has been previously described in the context of 
D-luciferin, and is known to raise the Km but cause minimal disruption of catalytic 
activity (Branchini et al., 2001).  
 
 
 
 
Table 2-2.  Apparent Km and Vmax values. Dose-response curves for purified 
luciferases (WT, T251S, L286M, S347A, and R218K) were generated with D-Luciferin, 
6’-NH2LH2, 6’-MeNHLH2, 6’-Me2NLH2, CycLuc1 and CycLuc2 at concentrations from 
0.122-125 M. The assays were performed in triplicate and represented as the mean ± 
SEM (Figure 2-4). Each curve was fit to the Michaelis-Menten equation by nonlinear 
regression (GraphPad 5.0) to determine apparent Km and Vmax values. 
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Figure 2-4.  Characterization of luciferase mutants.  Dose-response curves for purified 
luciferases (WT, T251S, L286M, S347A, and R218K) were generated with D-Luciferin, 
6’-NH2LH2, 6’-MeNHLH2, 6’-Me2NLH2, CycLuc1 and CycLuc2 at concentrations from 
0.122-125 M. The assays were performed in triplicate and are represented as the mean ± 
SEM. Each curve was fit to the Michaelis-Menten equation by nonlinear regression 
(GraphPad 5.0) to determine apparent Km and Vmax values (Table 2-2). 
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The most selective luciferase mutants were S347A and S347T. Because the 
activity of the purified S347T luciferase was found to decline rapidly when stored at 4˚C, 
S347A was used in preference to S347T for further characterization (Figure 2-5). The 
S347A luciferase yielded a 14-fold increase in light emission for CycLuc1, equivalent to 
that of the R218K mutant, while simultaneously decreasing the maximal emission from 
D-luciferin by 7.5-fold and raising the Km for D-luciferin by >10-fold (Figure 2- 4; Table 
2-2). To determine whether this selectivity could be further increased, we created several 
combinations of the S347A mutation with T251S, L286M, or F247 mutants (Figure 2-5). 
All of these mutants showed increased discrimination against D-luciferin, giving even 
lower light output than with S347A alone. On the other hand, the S347A/L286M double 
mutant further increased the maximal sustained light emission from CycLuc1 by two-fold 
relative to S347A alone, albeit with a ~10-fold increase in the Km to 22 M.  
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Figure 2-5. Several S347 mutants show selectivity for CycLuc1 over D-Luciferin. (A) 
Purified WT, S347A, S347T mutant luciferases (10 nM) were used in titration assays of 
the native substrate D-Luciferin and CycLuc1 at concentrations from 0.122-125 M.  The 
assays were performed in triplicate and are represented as the mean ± SEM.  (B)  Purified 
S347A and double and triple mutants (10 nM) were used in titration assays of the native 
substrate D-Luciferin and CycLuc1 at concentrations from 0.122-125 M. 
 
 
Rapid injection experiments were performed to reveal the burst kinetic behavior 
of the mutant luciferases (Figure 2-6; Figure 2-7). As we have observed for the wild-type 
protein, most alkylaminoluciferin substrates gave a rapid initial burst of light, followed 
by a substantial decrease in the rate of light output (Reddy et al., 2010). Although most of 
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the mutant luciferases identified here shared this general behavior, the decrease in the rate 
of light output was less severe than that of the wild-type protein, resulting in a higher 
level of sustained light emission (Figure 2-6; Figure 2-7A). The most striking finding was 
that the initial rate of light output for the dialkylaminoluciferin CycLuc2 with the mutant 
R218K is considerably increased relative to the wild-type protein (Figure 2-6; Figure 2-
7B). In contrast, the burst kinetic profile for the corresponding acyclic 
dialkylaminoluciferin 6’-Me2NLH2 was largely unchanged (Figure 2-6; Figure 2-7C).  
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Figure 2-6. Burst kinetics and emission profiles. Burst emission profiles for purified 
6’-NH2LH2, 6’-MeNHLH2, 6’-Me2NLH2, CycLuc1 and CycLuc2 as described in the 
Methods. For ease of comparison between mutants, the burst emission scale is the same 
for all mutants used with a particular substrate. For comparison between substrates, note 
the relative emission on the Y-axis differs to account for the differences in relative light 
output. Emission spectra were also determined for each protein-substrate pair and are not 
normalized. 
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Figure 2-7. Burst kinetic profiles with WT and R218K luciferases. Purified 
luciferases (10 nM) were rapidly injected at the 10-second time point into 10 M of 
CycLuc1 (A), CycLuc2 (B), or 6’-Me2NLH2 (C) and the light emission was recorded. 
 
 
The bioluminescence emission wavelength of aminoluciferins is red-shifted 
relative to D-luciferin with all of the tested luciferases (Table 2-3). Because the PMT in 
the Turner Veritas plate reader is less sensitive to the red-shifted light emission of the 
aminoluciferin substrates than the green light emission of D-luciferin, this likely leads to 
an underestimation of the true light output for aminoluciferins. We did not attempt to 
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correct for this difference, which also varies among mutants. For example, the R218K 
luciferase caused a slight red-shift in the bioluminescence of all luciferins: D-luciferin 
yields maximal emission at 567 nm, CycLuc1 at 609 nm, and CycLuc2 at 621 nm (Table 
2-3). In contrast, the L286M mutant results in a 5-13 nm blue-shift in the emission of all 
aminoluciferins, but a diametrically-opposed 13 nm red-shift in D-luciferin light emission 
(Table 2-3). Interestingly, the S347A mutant gives discrete emission peaks for all of the 
aminoluciferins, but anomalous bimodal emission for D-luciferin (Branchini et al., 2003).  
 
 
 
 
Table 2-3.  Emission maxima. Emission spectra for purified luciferases (WT, T251S, 
L286M, S347A, and R218K) were generated with D-Luciferin, 6’-NH2LH2, 6’-
MeNHLH2, 6’-Me2NLH2, CycLuc1 and CycLuc2 as described in the Methods.  Emission 
maxima are presented here in nm. 
 
 
 
Characterization of Mutants in Mammalian Cells 
The mutant luciferases that performed best in vitro were cloned into pcDNA3.1 
and transfected into CHO-K1 cells. Light emission from mutant luciferases in CHO cell 
lysates generally mirrored the results with purified proteins (Figures 2-2, 2-3, 2-4, and 2-
8).  The lone exception was L286M, which gave lower light output than expected, 
possibly indicating that this protein has a lower expression level and/or stability in the 
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cellular context (Figures 2-2, 2-3, 2-4 and 2-8). Unsurprisingly, D-luciferin was the best 
substrate for wild-type luciferase (Figure 2-8; 2-9A).  However, for the R218K and 
T251S mutant luciferases, CycLuc1 light output was superior to D-luciferin at substrate 
concentrations below ~30 M. In the case of the S347A mutant, CycLuc1 exceeded the 
light output of D-luciferin over the entire concentration range (Figure 2-8,  2-9A). All 
other substrates had considerably lower levels of light emission in cell lysates, with the 
exception of 6’-aminoluciferin with the mutant F247L (Figure 2-2B).  
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Figure 2-8. Dose-response profiles from luciferin substrates in CHO-K1 cell lysate. 
CHO-K1 cells were transiently transfected with pcDNA3.1 vectors expressing WT, 
T251S, L286M, S347A or R218K firefly luciferase. Dose-response curves for each 
luciferase with D-Luciferin, 6’-NH2LH2, 6’-MeNHLH2, 6’-Me2NLH2, CycLuc1 and 
CycLuc2 were generated at concentrations from 0.122-125 M using lysates from the 
transfected cells. The assays were performed in triplicate and are represented as the mean 
± SEM. 
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Figure 2-9. Dose-response profiles from luciferases in expressed in CHO-K1 cell 
lysates and in live cells. CHO-K1 cells were transiently transfected with pcDNA3.1 
vectors expressing WT, T251S, L286M, S347A, or R218K firefly luciferase. Dose-
response curves for each luciferase with D-Luciferin, 6’-NH2LH2, 6’-MeNHLH2, 6’-
Me2NLH2, CycLuc1 and CycLuc2 were generated at concentrations from 0.122-125 M 
using lysates from the transfected cells (A) or using the intact live cells (B). The assays 
were performed in triplicate and are represented as the mean ± SEM. 
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The light output from  luciferase in live cells is much lower than that of lysed 
cells, as has been previously observed for D-luciferin (de Wet et al., 1987; Craig et al., 
1991; Shinde et al., 2006) and 6’-aminoluciferin (Shinde et al., 2006). Moreover, there is 
less difference in the relative levels of light emission between different substrates. Even 
with the wild-type luciferase, CycLuc1 emitted 26% of the light of D-luciferin at 125 M 
and its light output greatly exceeded that of 6’-aminoluciferin (Figure 2-9B).  CycLuc1 
was the superior substrate for T251S, R218K, and particularly S347A luciferase (18-fold 
higher light output than D-luciferin at 125 M). Remarkably, live-cell light emission 
from CycLuc2 exceeded that of both CycLuc1 and D-luciferin with T251S, S347A, and 
particularly R218K luciferase over a broad concentration range, despite the relatively 
poor light output from CycLuc2 in cell lysates (Figures 2-9 to 2-11). 
 57 
 
 
Figure 2-10. Relative activity of mutant luciferases and novel substrates in vitro, in 
CHO cell lysate, and in intact CHO cells at 1 µM substrate concentration.  The 
percentage of light output is expressed relative to light output with WT luciferase and the 
corresponding substrate under the same conditions. 
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Figure 2-11. Relative activity of mutant luciferases and novel substrates in vitro, in 
CHO cell lysate, and in intact CHO cells at 125 µM substrate concentration.  The 
percentage of light output is expressed relative to light output with WT luciferase and the 
corresponding substrate under the same conditions. 
 
 
 
Discussion 
We have found that mutation of firefly luciferase dramatically improves 
aminoluciferin substrate utilization and selectivity, and allow the use of these substrates 
to monitor luciferase expression in cells and cell lysates. For example, the F247L mutant 
improves light output from 6’-aminoluciferin by almost five-fold and can be 
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recommended for improved imaging of this substrate (Figure 2-1; Figure 2-2). This has 
particular significance for bioluminescence assays of protease activity that rely on 
detection of this substrate (Monsees et al., 1994; Shah et al., 2005; Fan et al., 2007; 
Dragulescu-Andrasi et al., 2009; Hickson et al., 2010; Scabini et al., 2011). Light output 
from all aminoluciferins was greatly increased by the R218K mutant (e.g., 14-fold for 
CycLuc1, 20-fold for CycLuc2), suggesting this mutant as a starting point for measuring 
light emission from these and other novel alkylated aminoluciferins.  Moreover, mutation 
of serine 347 to threonine or alanine gives similarly improved light emission from 
CycLuc1 but also exhibits strong selectivity for CycLuc1 over D-luciferin both in vitro 
and in live cells (Figures 2-4; Figures  2-9 to 2-11). Combination of mutations such as the 
ones described here is expected to allow further enhancement of aminoluciferin light 
output and selectivity. For instance, we have found that the S347A/L286M double mutant 
gives twice the light output of S347A with CycLuc1, and further discriminates against D-
luciferin (Figure 2-5). 
The rate at which light is generated by luciferase is dependent on several factors, 
including the rate of adenylation and oxidation to afford the oxyluciferin excited state, the 
quantum yield of light emission, and the rate of product release. To gain insight into the 
underlying mechanisms by which light emission is improved, we obtained burst kinetic 
profiles of the luciferase mutants (Figure 2-6; Figure 2-7). For CycLuc1 and 6’-
MeNHLH2, all mutants result in a rapid initial burst that is similar to that observed for the 
wild-type protein, but with higher sustained light output (Figure 2-6; Figure 2-7A). 
Notably, both the burst and sustained light emission from CycLuc1 exceeds that of 6’-
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MeNHLH2 with all of the luciferases we have characterized, and is consistent with a role 
for cyclization in optimizing aminoluciferin light output (Reddy et al., 2010). The rapid 
rise to a high initial rate of light output for these substrates suggests that there are no 
substantive defects in the formation of the respective luciferyl-AMP or its subsequent 
oxidation to afford the excited-state oxyluciferin. We therefore presume that a reduction 
in affinity for aminoluciferin substrates and the corresponding lowered affinity for their 
products is primarily responsible for the observed improvement in sustained light 
emission for most of the mutants we have identified. Even with D-luciferin, the 
molecular basis for product inhibition is still unresolved, potentially including 
contributions from both dehydroluciferyl-AMP (L-AMP) and oxyluciferin (Fraga, 2008). 
Thus, it is also possible that some mutants function in part by reducing the formation of 
the corresponding L-AMP analog. A better molecular understanding of the nature of the 
product inhibition with these substrates may help guide future optimization efforts. 
Like CycLuc1, light emission from CycLuc2 is superior to its acyclic counterpart 
6’-Me2NLH2 for every luciferase we have tested. Intriguingly, we find that the burst 
emission for CycLuc2 with the mutant luciferase R218K is substantially more rapid and 
intense than that of CycLuc2 with wild-type or any other mutant (Figure 2-6; Figure 2-
7B). In contrast, the burst for 6’-Me2NLH2 is rapid but weak for all mutants (Figure 2-6; 
Figure 2-7C). We postulate that in the wild-type luciferase, the rigidity of CycLuc2 – 
which is desirable for efficient light emission – also enforces a sub-optimal alignment in 
the active site for the production of the excited-state oxyluciferin (e.g., delayed 
adenylation or oxidation; see Figure 1-1). Enlarging the luciferin binding pocket with the 
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R218K mutation improves the alignment of CycLuc2 within the active site, allowing 
more rapid production of an efficient light-emitting oxyluciferin excited state (Figure 2-
7B). Conversely, the free bond rotation about the aryl amine bond of 6’-Me2NLH2 may 
facilitate the alignment necessary for the rapid formation of the oxyluciferin, but also 
limit the efficiency of light output (Figure 2-7C). 
For light emission from live cells, the cell-permeability and Km of the substrate 
are important for access to the intracellular luciferase and the efficiency of light output 
under sub-saturating concentrations. CycLuc2 has a lower Km than CycLuc1 (Table 2-2) 
and is predicted to be more cell-permeable than CycLuc1 because of the replacement of a 
polar amine proton with a methyl group (cLogP of 2.5 versus 2.0). These differences are 
therefore likely to explain the better relative performance of CycLuc2 in live versus lysed 
cells. Moreover, this suggests that optimization of cell permeability and light output at 
low substrate concentrations – rather than just maximal light output – may be particularly 
important for imaging in live cells and organisms, because insufficient substrate is 
delivered into the live cell to achieve maximal light emission.   
The bioluminescence emission wavelength of D-luciferin from different beetle 
luciferases (firefly, click beetle, railroad worm) and their mutants varies from ~540-635 
nm (Viviani et al., 1999; Branchini et al., 2010). Beyond simple changes in the polarity of 
the environment of the light emitter (Morton et al., 1969), explanations for this sensitivity 
include changes in the rigidity of the active site (Nakatsu et al., 2006) and perturbations 
in the ionic interactions of the phenolate of D-luciferin (Hirano et al., 2009). The 
emission behavior of aminoluciferins can lend insight into this question because they lack 
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an ionizable phenolate (Figure 1-7). With the mutant R218K, all luciferins exhibit a 
modest red-shift in emission wavelength (Table 2-3). Because oxyluciferins are 
asymmetric charge-transfer molecules, some shared solvatochromatic sensitivity to the 
polarity of the luciferin binding site is expected (Naumov et al., 2009). However, with 
other mutants we find that D-luciferin exhibits anomalous emission behavior: the L286M 
mutation causes a red-shift in the emission of D-luciferin but a blue-shift in the emission 
of all aminoluciferins, and D-luciferin uniquely gives bimodal emission with S347A 
(Table 2-3). These differences are consistent with a role for the ionization state and ionic 
interactions of the phenol in determining the bioluminescence emission wavelength when 
D-luciferin is the substrate.  
 The efficient chemical generation of light by firefly luciferase has been widely 
used as a sensitive reporter system for gene expression (de Wet et al., 1987; Prescher et 
al., 2010). However, the application of bioluminescence detection as a general optical 
reporter of cellular status has lagged behind that of fluorescence. Chemical modification 
of the luciferin substrate can red-shift the emission wavelength of bioluminescence 
beyond that of D-luciferin (Reddy et al., 2010). Moreover, the combination of synthetic 
luciferins and mutant luciferases described here not only extends the wavelength of 
bioluminescence emission and broadens the scope of substrates that can be used for 
bioluminescent assays both in vitro and in mammalian cells, but also suggests that 
orthogonal luciferases could be developed to allow multiplexing of bioluminescent 
signals. Further chemical modification of luciferin substrates and corresponding mutation 
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of firefly and other beetle luciferases is therefore anticipated to be a fruitful avenue for 
expanding the power and scope of bioluminescence assays and imaging. 
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CHAPTER III: Improving Bioluminescence Imaging Discussion  
 
Bioluminescent imaging studies in tissue and whole organisms necessitate the use 
of luciferases that can emit longer wavelength, deeper penetrating red light. Red-emitting 
luciferases for imaging studies have been generated through mutagenesis and by taking 
advantage of naturally red-emitting luciferase variants (Almond et al., 2003; Branchini et 
al., 2010a; Branchini et al., 2007a; Branchini et al., 2005a; Kitayama et al., 2004; 
Nakajima et al., 2004; Viviani et al., 1999).  Using saturating mutagenesis of specific 
residues in firefly luciferase, we were able to generate mutant luciferases that emitted 
more intense, sustained red-shifted light with novel luciferin analogs made in the lab than 
WT protein.  These mutant:luciferin pairs present an alternative method for generating 
red light, expanding the toolset for bioluminescence imaging.  
Future directions could include the optimization of these mutant:luciferin pairs to 
emit even more red shifted, higher intensity sustained light.  We found that in live cells, it 
appears that the highest light output was observed with mutants that had high substrate 
affinity and with substrates that were the most hydrophobic.   Future screens to identify 
mutants that could best utilize different luciferin substrates in vivo would focus not just 
on mutants that exhibited the highest Vmax values, but also those that maintained low Km 
values with the substrates with the most favorable cLogP values.  Also, several additional 
novel luciferins have been generated in the lab (Figure 3-1) that are more hydrophobic 
and emit even more red-shifted light (Figure 3-2).  Screens with these compounds could 
also generate luciferases that would perform well in vivo. 
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Fig 3-1. Additional novel alkylamino luciferin substrates.  Following screening with 
D-Luciferin, 6’-NH2LH2, 6’-MeNHLH2, 6’-Me2NLH2, CycLuc1 and CycLuc2, these 
additional novel alkylamino luciferin molecules were screened with the mutant R218K. 
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Figure 3-2. Emission maximum with R218K and novel substrates.  Several novel 
alkylamino luciferin substrates further red shift light emission from the R218K mutant of 
luciferase. 
 
 
Furthermore, future efforts would include the quantification of both the 
expression levels of the different luciferase mutants in CHO cells and the achievable 
intracellular concentrations of each substrate in intact cells.  One way to measure 
substrate concentrations would be through direct fluorescent measurement of live cells 
treated with substrate.  The results of these experiments could allow for more definitive 
conclusions to be made about the relative roles of Vmax, Km and cellular permeability in 
the overall amount of light produced by each of the mutants.  Quantification of the 
expression levels of the different mutants could also explain the slight differences in light 
output observed in the in vitro studies and in the experiments with CHO cell lysate.  
Further, the imaging studies of live cells treated with substrate would allow for the 
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verification that specific substrates do not accumulate in certain subcellular locations, but 
exhibit homogenous localization profiles. 
In addition, while we found that combining the mutations that were best able to 
utilize our synthetic substrates did not generally improve their functioning (Figure 3-3) 
(many exhibited higher Vmax values and/or substrate selectively, but all had higher Km 
values which are unfavorable for in vivo applications), saturating mutagenesis at those 
sites in the context of the mutant background could potentially prove more fruitful.  An 
alternate approach to generate luciferases with improved ability to utilize our novel 
substrates would be to perform DNA shuffling or exchange of restriction fragments 
among the various luciferase variants and perform screens with the resulting chimeras 
(Joern et al., 2002; Wood, 1990; Zhang et al., 2002).   
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Figure 3-3.  Combining favorable mutations can increase Vmax with our novel 
synthetic substrates, but at a cost to Km values. Purified double and triple mutants (10 
nM) were used in titration assays of the native substrate D-Luciferin and CycLuc1 at 
concentrations from 0.122-125 M. 
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Interestingly, S347A showed a great deal of selectivity with respect to the 
substrate CycLuc1 as opposed to D-luciferin (Figures 2-9 to 2-11).  This observation 
supports the possibility of using S347A:CycLuc1 in combination with WT:D-luciferin for 
dual color studies or multiplexing applications to allow for the monitoring of multiple 
events in the same lysate, cell, tissue or organism.  Screening for luciferase mutants with 
even lower light emission with D-luciferin would further improve the imaging 
possibilities. 
Overall, in vitro and in cell lysate, the substrate CycLuc1 and the mutants S347A 
and R218K exhibited the highest relative light output of the mutants and novel substrates 
tested (Figure 2-4; Figure 2-8).  However, the ultimate goal of this work would be to 
demonstrate that our novel luciferin substrates and luciferase mutants could be used to 
perform bioluminescent imaging in a mouse and apply this technique to in vivo 
applications.  While they exhibit lower light output with CycLuc2 in vitro and in cell 
lysate, the T251S, S347A and R218K mutants emit high relative levels of red-shifted 
light with CycLuc2 over a wide range of substrate concentrations in live cells (Figures 2-
9 to 2-11).  The red-shifted light emitted by these mutants would greatly improve the 
degree of resolution achievable, making them potential candidates for use with CycLuc2 
in mouse models for a variety of applications, including the noninvasive tracking of viral 
loads or tumor metastasis in the live mouse, or even in the different patterns of gene 
expression in a developing mouse.  The combination of our mutants with mutations that 
improve thermostability and codon optimization would also aid in this process. 
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Overall, methods to better observe cellular activity will allow for the improved 
understanding of the events that lead to the development of disease states.  In parallel, 
methods that can allow for the precise control of cellular events, through the control of 
protein activation states, would also provide great insight into disease development. 
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CHAPTER IV: Photocaging background 
 
The ability of a cell to establish, maintain, and modulate a polarized state is 
essential for proper cellular behavior, such as mitosis, migration, differentiation, 
proliferation, and morphogenesis.    The signaling pathways that allow the cell to achieve 
this control require activation of cellular components at specific times and in specific 
locations.  Misregulation of these important signaling pathways can lead to many disease 
states.  Reagents that modulate components of these pathways can provide insight into 
the fundamental spatial and temporal activation requirements in a living cell.   
 
Methods to control protein activity 
Numerous methods have been developed to control the activity of proteins.  One 
approach is the expression or overexpression of genes coding for mutant proteins that 
exhibit specific properties.  Some of these include proteins that are always activated and 
performing their given function, termed constitutively active (CA), those that are able to 
exert inhibitory action on their wild-type counterparts, termed dominant negative (DN), 
or those that are generally inactive or exhibit some other mutant function.  One method to 
generate the mutants is through site-directed mutagenesis.  Site-directed mutagenesis has 
been key to the analysis of protein function both in vitro and in vivo, however the 
functionality of the potential groups incorporated is restricted to the twenty genetically 
encoded amino acids.  Small interfering RNAs, or siRNAs, are also a powerful tool to 
reduce the intracellular concentration of a protein of interest.  The protein concentration 
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is reduced via the RNA interference (RNAi) pathway, whereby a messenger RNA is 
prevented from producing the protein it encodes.  While the use of RNAi does allow for 
modulation of the degree of reduction of protein levels, both its use and the expression of 
mutant proteins present similar limitations.  First, they are limited in their temporal and 
spatial resolution.  Mutants will be present throughout the cell and could exert their 
effects throughout the cell cycle and at many subcellular locations.  Likewise, siRNA 
effects are widely realized in the cell to which they are applied.  Another drawback of 
both of these methods is that they require time to take effect, so there is the potential for 
the cell to compensate for the presence of the mutant protein or the reduction in or lack of 
protein resulting from siRNA treatment.   
Another approach is the use of small molecules that behave as inhibitors, 
activators, or modulators of protein activity.  The effects of these types of molecules are 
realized much more quickly, eliminating the concerns of cellular compensation.  
However much like the use of mutants and siRNA, inhibitors, activators, or modulators 
of protein activity are also limited in their spatial and temporal resolution.  Furthermore, 
these types of molecules often do not possess the required degree of target specificity. 
Several methods have been developed to improve the utilization of small 
molecules in the control of protein function, including ‘bump-and-hole’ methods and the 
use of chemical inducers of dimerization.  In ‘bump-and-hole’ methods, a protein is 
mutated at a location near the active site, for example, to introduce a cavity, or hole.  An 
inhibitor of the protein is derivatized with a bulky group, or bump, designed to fit into the 
space introduced by the mutation.  Thus, the mutant protein will interact specifically with 
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the ‘bumped’ inhibitor that the wild type protein will not be able to recognize, allowing 
for allele-specific inhibition.  The ‘bump-and-hole’ approach has been used to study 
many proteins including kinesins, nuclear hormone receptors, and the transcription factor 
EF-Tu (Belshaw, 1995; Hwang and Miller, 1987; Kapoor and Mitchison, 1999; Powers 
and Walter, 1995; Shogren-Knaak et al., 2001).  Chemical inducers of dimerzation (CID) 
also allow for the control of protein activity by rapidly bringing together two proteins.  
One commonly used CID is rapamycin.  When two proteins are expressed as a fusion 
with the FK506-binding protein (FKBP12) and a fusion with the FKBP12-rapamycin-
associated protein (FRAP), addition of rapamycin will result in dimerization of FKBP 
and FRAP, bringing the two fused species in close proximity.  For example, this method 
was used to bring together two halves of a split intein domain to allow for the conditional 
protein splicing upon rapamycin addition (Mootz et al., 2003; Mootz and Muir, 2002).  
Another CID is 4-hydroxy-tamoxifen, which can be used to bring together two proteins 
fused to the ligand-binding domain of the estrogen receptor (Buskirk et al., 2004).  As 
with inhibitors, activators or modulators of protein activity, ‘bump-and-hole’ methods 
and CIDs benefit from quick action upon addition of the ‘bumped’ inhibitor or 
dimerizing molecule.  Additionally, by design these approaches also benefit from a high 
degree of specificity.  Unfortunately, they are also unable to achieve spatial resolution in 
the context of a living cell. 
Chromophore-assisted light inactivation (CALI) is a method to rapidly inactivate 
a protein of interest (Jay and Sakurai, 1999).  In this approach, a chromophore produces 
reactive oxygen species (ROS) when irradiated with light and these ROS damage proteins 
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located very close to the chromophore.  Typically the chromophore is fused to antibodies 
towards the protein of interest or directly to the protein itself.  Factors that impact the 
radius of damage include the specific chromophore selected and the intracellular 
environment in which CALI is being performed.  CALI can be a powerful approach to 
allow for spatial and temporal protein inactivation when experiments are designed 
stringently and proper controls are in place.  However there is still some doubt regarding 
both the specificity and general applicability of this approach due to the possibility of 
unintentional concomitant damage (Jacobson et al., 2008).  
 
Photocaging introduction 
Photocaging is an approach that addresses many of the limitations described 
above.  Specifically, a photocaged species possesses a modification at a functionally 
relevant position that is sensitive to illumination by light.  Therefore when a photocaged 
molecule is introduced into a cell it will not be able to perform its usual functions.  
However, irradiation will remove the modification, freeing the species at that specific 
time and place in the cell and allowing questions regarding its intracellular roles at 
specific locations and cell cycle stages to be addressed. This approach is particularly 
powerful in that cells are transparent, they do not themselves respond to light unless they 
are highly specialized cells like photoreceptors cells, and the methods of controlled light 
illumination are well established.  
While many light sensitive protecting groups used for synthetic chemistry 
applications had been previously described (Barltrop et al., 1966; Herbert and Gravel, 
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1974; Kirby and Vagelos, 1967; Patchornik et al., 1970), Kaplan and coworkers were the 
first to use a caged molecule for biological light based activation experiments (Kaplan et 
al., 1978).  Specifically, they used 2-nitrobenzyl phosphate and 1-(2-nitro)phenylethyl 
phosphate to cage adenosine triphosphate (ATP) and render it nonhydrolyzable by the 
protein they were interested in studying, the Na:K ATPase.  Upon irradiation with light, 
the uncaged ATP was once more a substrate for the Na:K ATPase and studies of ATP 
utilization by the Na:K ATPase could be performed. Since then, caged ATP has been 
used widely (Goeldner and Givens, 2005; Marriott and Ottl, 1998; Marriott et al., 1998) 
and many other small molecules including lipids, sugars, steroids and second messengers 
have also been caged and used to investigate a wide variety of biological questions 
(Dorman and Prestwich, 2000; Juodaityte and Sewald, 2004; Kale et al., 2001; Srinivas et 
al., 2002, 2005). 
Caged peptides can also be synthesized using automated solid phase methods 
where residues whose side chains can be derivatized are lysine, arginine, tyrosine, serine, 
cysteine, glutamic acid and aspartic acid. The first reported use of caged peptides in a 
biological system involved the use of peptide inhibitors of myosin light chain kinase 
(MLCK) and Ca/calmodulin that were caged with 2-bromo-2’nitrophenylacetic acid 
methyl ester on the phenolic group of a tyrosine side chain (Walker et al., 1998).  These 
caged peptides were used to investigate the degree to which eosinophil cells rely on 
calmodulin and MLCK to control their amoeboid locomotion. 
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Direct chemical modification 
Overall, there are many different types of photocages that can be used to cage 
small molecules and peptides.  However, generating photocaged proteins has proved 
more challenging.  Photocaged proteins have been generated in several ways.  The first is 
by direct chemical modification of a native amino acid side chain of interest or that of an 
amino acid, most often a cysteine residue, introduced by site-directed mutagenesis at a 
certain location in the protein.   
Some of the first processes that were photocaged using this method include G-
actin polymerization (Marriott, 1994), the ATPase activity of myosin (Marriott and 
Heidecker, 1996), the enzymatic activity of -galactosidase (Golan et al., 1996), the 
kinase activity of cAMP-dependent protein kinase (Chang et al., 1998; Curley and 
Lawrence, 1998b), the toxic pore forming ability of -hemolysin (Chang et al., 1995), 
and the actin binding and severing activity of cofilin (Ghosh et al., 2002; Ghosh et al., 
2004). In all of these examples, cysteine or lysine residues were caged using various 
ortho-nitrobenzyl derivatives.  These small molecules, when irradiated with UV light, 
undergo the transfer of an oxygen from the nitro group to the benzylic position.  Because 
the benzylic position is substituted with either an oxygen, sulfur or nitrogen group, the 
transfer of the oxygen generates an unstable intermediate that decomposes to the 
corresponding ortho-nitroso derivative and restores the modified amino acid to its 
original state (Figure 4-1).  When generating photocaged protein in this manner, factors 
such as residue accessibility, the potential for modification on multiple residues, the 
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generation of a mixed protein population, and removal of unmodified protein become 
considerations.   
 
    
 
 
Figure 4-1.  Ortho-nitrobenzyl uncaging.  Mechanism of Ortho-nitrobenzyl uncaging 
upon irradiation of caged protein with h.  L=leaving group which here is the amino acid 
side chain which was modified, often the sulfur group of a cysteine. 
 
 
Another slightly different method to generate photocaged proteins is through 
protein-catalyzed activation of a specific residue followed by alkylation with the 
photolabile moiety.  Zou and coworkers activated a threonine residue in the catalytic 
subunit of protein kinase A by thiophosphorylation with the protein 3-phosphoinositide-
dependent kinase 1 (PDK-1), which they subsequently derivatized with 4-
hydroxyphenacyl bromide (Zou et al., 2002).  This approach relied on the selective 
phosphorylation of the threonine of interest by PDK-1. 
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Banghart and coworkers used an azobenzene derivative, substituted with a 
maleimide moiety to make it cysteine reactive, to photocage a cysteine introduced into 
the potassium channel Shaker (Banghart et al., 2004).  Irradiation with long-wavelength 
light shifts the azobenzene moiety to an extended trans configuration and short-
wavelength light returns it to a cis configuration.  In the extended trans configuration, a 
quaternary ammonium addition on the azobenzene is close enough to block the pore of 
the channel.  Banghart et al (2004). expressed the mutant Shaker channel in Xenopus 
oocytes and in hippocampal pyramidal neurons and treated with high external levels of 
the azobenzene derivative to block Shaker potassium channels.  This approach is unique 
in that it allows for reversible light dependent block of the channel.   
 
Expressed protein ligation 
Photocaged proteins can also be generated using expressed protein ligation (EPL).  
Hahn and Muir used EPL to generate Smad2 photocaged on two activating phosphoserine 
residues (Hahn and Muir, 2004).  This method takes advantage of native chemical 
ligation in which a recombinant protein with a C-terminal thioester and a synthetic 
peptide with an N-terminal cysteine are fused through a native peptide bond.  
Specifically, C-terminally-truncated recombinant Smad2 protein was expressed upstream 
of an intein-chitin binding domain sequence.  A nitrogen to sulfur acyl shift changes the 
amide linkage between Smad2 and the intein to a thioester bond involving the intein's 
active site cysteine.  Subsequent thiolysis generates recombinant Smad2 containing a C-
terminal thioester.  This was then ligated to a caged phosphopeptide synthesized using 
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solid phase methods to possess an N-terminal cysteine and 2-nitrophenylethyl caged 
phosphorylated serines.  While EPL has also been used to generate “activated” proteins, 
for example through the incorporation of phosphomimetic modifications such as non-
hydrolysable phosphotyrosine modifications (Lu et al., 2001), without the photolabile 
caging moiety that approach is subject to the same limitations as expressing mutant 
proteins. 
 
Unnatural amino acid mutagenesis 
Nonsense suppression mutagenesis (Wang and Schultz, 2002) has also been used 
to generate photocaged proteins.  This method permits unnatural amino acids to be 
introduced at a specific location in a protein, allowing for new functionality outside that 
available in the twenty naturally encoded amino acids, providing that the ribosome can 
accept the novel unnatural amino acid.  Some of the first proteins to be caged in this 
manner were T4 lysozyme, the active site of which was caged by introducing an aspartyl 
-o-nitrobenzyl ester in place of an essential aspartic acid residue (Mendel et al., 1991), 
and the GTPase p21Ras, which was caged by introducing an aspartyl -o-nitrobenzyl ester 
in place of an aspartic acid reside at a location that is essential for interaction with the 
GTPase activating protein p120-GAP (Pollitt and Schultz, 1998).  Miller and coworkers 
also generated photocaged nicotinic acetylcholine receptors by introducing ortho-
nitrobenzyl tyrosine in place of tyrosine in the protein using unnatural amino acid 
mutagenesis.  Because they did this in Xenopus oocytes, they were able to perform in 
vivo electrophysical studies of the behavior of a protein in a time-resolved manner (Miller 
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et al., 1998).  Nonsense suppression mutagenesis does have limitations however; not a 
great deal of protein is generated using this method and overall, the process of unnatural 
amino acid mutagenesis itself is not trivial.  In addition, the photocage moiety is 
constrained to a single preselected structure, and since there is the possibility that the 
modification may fail to make the protein behave as anticipated, the generation of the 
caged protein with the desired properties can be lengthy. 
Another consideration for all of the methods described above, with the exception 
of the work done by Miller and coworkers in Xenopus oocytes, is that the caged protein is 
generated in vitro and must be introduced into living cells.  In the instances where studies 
were performed in living cells, this was achieved by microinjection of single cells. 
 
Phytochrome fusion proteins 
Proteins that are themselves responsive to light can also be used to generate 
photosensitive proteins.  For example, Leung and coworkers employed a genetic 
approach to allow for the photoactivated polymerization of actin (Leung et al., 2008).  In 
these studies, they fused the Rho GTPase Cdc42 to the light-sensing domain of 
phytochrome B (PhyB) and Cdc42’s effector Wiskott-Aldrich Syndrome Protein (WASP) 
to the light dependent PhyB binding domain of phytochrome interacting factor 3 (Pif3).  
Thus, upon irradiation with red light, PhyB and Pif3 bind to one another, bringing Cdc42 
and WASP in close proximity and allowing Cdc42 to activate WASP, which resulted in 
activation of the ARP2/3 complex and subsequent actin assembly.   
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Overall, photocaging is a powerful method to allow for the control of cellular 
function through the alteration of protein activation states in a spatial and temporal 
manner.  A family of proteins called the Rho GTPases are a prime example of a proteins 
whose study could further benefit from methods like photocaging. 
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CHAPTER V:  Rho GTPase Background 
 
Introduction 
The family of proteins called the Rho GTPases are typically thought of in terms of 
their role in controlling the dynamics of the actin and microtubule cytoskeleton, allowing 
them to modulate the cell’s ability to maintain a polarized state.  Rho GTPase control of 
cellular polarity is also important to ensure proper cytoskeletal dynamics throughout the 
cell cycle and in cellular processes such as phagocytosis, targeted vesicle secretion, axon 
and dendrite formation, and migration.   These proteins are also involved in apoptosis, 
gene expression and the immune response and as a result, improper Rho GTPase 
signaling is associated with many disease states, including cancer, hypertension, diabetes, 
asthma, pathogenic infection, and neurological disorders (Boettner and Van Aelst, 2002).  
The Rho GTPase family of proteins makes up one of the branches of the Ras 
superfamily of small GTP binding proteins (Colicelli, 2004; Wennerberg et al., 2005). 
The Rho GTPase family consists of twenty-five proteins encoded by twenty-two genes.  
The family can be further divided into subfamilies based on homology, including the 
Rho-like GTPases RhoA, B, and C, the Rac-like GTPases Rac1, 2, 3, and RhoG and the 
Cdc42-like GTPases Cdc42, TcL, Tc10, Wrch1 and Wrch2 (Wennerberg and Der, 2004). 
The gene encoding the Rho GTPase RhoA was the first to be identified (Madaule and 
Axel, 1985), followed by those encoding Rac1 and Rac2 (Yamamoto et al., 1988), and 
that encoding Cdc42 (Munemitsu et al., 1990). These ~21 kDa proteins are found in all 
eukaryotic organisms.  Of the Rho GTPases, RhoA, Rac1, and Cdc42 are best 
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characterized and classically have been credited with controlling stress fiber and focal 
adhesion formation, lamellipodia formation, and filopodia formation, respectively (Nobes 
and Hall, 1995; Ridley and Hall, 1992).    
 
Factors that control Rho GTPase activation states 
Cellular control of the location and timing of Rho GTPase activation is important 
to maintain proper Rho GTPase signaling. In general, Rho GTPases can be thought of as 
tightly regulated molecular “switches” whose activation state is controlled by several 
families of proteins (Figure 5-1). Guanine-nucleotide exchange factors (GEFs) activate 
GTPases by promoting the disassociation of GDP and its replacement with GTP 
(Erickson and Cerione, 2004; Hoffman and Cerione, 2004; Whitehead et al., 1997).  
GTPase-activating proteins (GAPs) turn the GTPases off by accelerating their rate of 
GTP hydrolysis (Moon and Zheng, 2003). Thus, the location of the GEFs and GAPs 
control where, when, and how long Rho GTPases are active. Over the years dozens of 
GEFs and GAPs have been identified.  Another family consisting of three proteins called 
Rho guanine nucleotide dissociation inhibitors (RhoGDIs) control GTPase activation 
states by sequestering GTPases in the cytosol and preventing both nucleotide exchange 
and hydrolysis (Fukumoto et al., 1990). Once active, GTPases are able to interact with 
effector proteins to promote their specific and localized effects.  Because the Rho family 
members are highly homologous, with 40-95% amino acid identity within the family 
(Wennerberg and Der, 2004), many of their GEFs, GAPs, and effectors possess 
overlapping specificity. This overlapping specificity, and the nature of the processes that 
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the Rho GTPases control, mean that tight spatial and temporal control of their activation 
is essential for their proper function. 
 
             
 
 
 
 
Figure 5-1.  Rho GTPase cycle.  Guanine-nucleotide exchange factors (GEFs) activate 
GTPases by promoting the disassociation of GDP and its replacement with GTP.  
GTPase-activating proteins (GAPs) turn the GTPases off by accelerating their rate of 
GTP hydrolysis.  Rho guanine nucleotide dissociation inhibitors (RhoGDIs) control the 
GTPase activation state by sequestering GTPases in the cytosol and preventing both 
nucleotide exchange and hydrolysis. Once active, GTPases are able to interact with 
effector proteins to promote their specific and localized effects. 
 
 
There is a wealth of structural information available about the Rho GTPase 
family.  Rho GTPases have been studied through X-ray crystallography and NMR 
spectroscopy in the inactive state complexed with GDP with (Wei et al., 1997) and 
without (Shimizu et al., 2000) Mg2+, in the active state complexed with non-hydrolyzable 
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GTP analogs (Hirshberg et al., 1997; Ihara et al., 1998), bound to GAP proteins (Rittinger 
et al., 1997a; Rittinger et al., 1997b), GEF domains (Rossman et al., 2002; Worthylake et 
al., 2000), effector domains (Dvorsky et al., 2004; Maesaki et al., 1999a; Maesaki et al., 
1999b), and RhoGDI (Hoffman et al., 2000; Longenecker et al., 1999; Scheffzek et al., 
2000), to name a few.  These studies have shed a great deal of light on the structural 
aspects of the GTPases that play a role in their regulation by these families of proteins, as 
well as the subtle changes that occur in the GTPase conformation upon activation.  
Posttranslational modification of the Rho GTPases also plays a role in their proper 
localization and function (Glomset and Farnsworth, 1994).  Specifically, many of the 
family members possess an isoprenylation site on their C-terminus (CAAX, where C is 
cysteine, A is any aliphatic amino acid, and X is the C-terminal amino acid) (Zhang and 
Casey, 1996).  After the GTPase is expressed, the protein CAAX prenyltransferase 
modifies the cysteine of the CAAX box with a prenyl group, either a farnesyl group or a 
geranylgeranyl group.  The last three amino acids are then removed by the Rce1 CAAX 
protease and the C-terminus of the GTPase is methylated by ICMT Methyltransferase 
(Adamson et al., 1992; Katayama et al., 1991; Roberts et al., 2008).  In general, Rho 
GTPases are thought to be in the cytoplasm when GDP-bound and inactive and localized 
to membranes when GTP-bound and active.  The specific membranes to which each 
family member localizes is thought to be dependent on the hypervariable C-terminal 
polybasic domain upstream of the prenylation site (Williams, 2003). 
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Active and Dominant Negative Rho GTPases 
Despite recognition of the importance of Rho GTPases in a wide variety of 
cellular processes, techniques used to study their activity often fail to appreciate 
spatiotemporal aspects of their regulation.  Much of what is known about the function of 
the Rho proteins has involved the use of dominant negative (DN) and constitutively 
active (CA) or fast cycling (FC) mutant forms of the proteins.  DN mutants possess a 
threonine to asparagine mutation at amino acid 17 (T17N) (Feig and Cooper, 1988; 
Powers et al., 1989) that makes them very poor magnesium binders (John et al., 1993), 
resulting in very low affinity for nucleotide.  Because GEF proteins no longer have to 
compete with nucleotide for binding in the nucleotide-binding pocket, their affinity for 
the DN GTPase is much higher.  Thus, when the DN GTPase is expressed in cells, it 
titrates available GEF protein away from endogenous GTPases, leaving them in an 
inactive or GDP bound state (Feig, 1999).   
In WT Rho GTPases, the glutamine at position 61 (Q61) coordinates a catalytic 
water molecule that is required for the hydrolysis of the bond between the  and  
phosphate of GTP.  CA mutants possess a mutation of either Q61 itself (Q61L), or 
another nearby amino acid (G12V), that makes them unable to coordinate the catalytic 
water necessary to hydrolyze GTP to GDP.  Thus, because there is approximately a 10 
fold excess of GTP relative to GDP in cells, CA mutants are locked in the active 
conformation and able to interact with effector proteins to cause downstream effects 
everywhere in the cell in which it is expressed.  These mutations were first identified in 
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the Rho-related GTPase Ras and have been found in more than 30% of all human tumors 
(Barbacid, 1987). 
Fast-cycling mutants, on the other hand, possess a mutation of phenylalanine 28 
to leucine (F28L), which removes the stabilizing  - orbital interactions between the 
nucleotide and the amino acid in the binding pocket (Lin et al., 1997; Lin et al., 1999).  
This allows FC mutants to load nucleotide on their own without the help of GEF proteins 
while maintaining their ability to hydrolyze GTP to GDP.  Again, due to the excess of 
GTP to GDP in the cell, FC mutants are constantly cycling to a GTP bound, or active 
conformation.  
While these mutants have been highly informative, their use is limited by the lack 
of control of the timing and location of GTPase activation.  DN and CA/FC mutants are 
off or on indiscriminately throughout the cell for times far exceeding that typical of their 
endogenous counterparts, making events controlled by their spatiotemporal 
inactivation/activation difficult to study.  Additionally, because GEFs can possess activity 
toward multiple GTPases (Zheng et al., 1995), which may change with changing cell 
cycle stage or intracellular location, the phenotypes resulting from expression of the DN 
form of one GTPase may actually result from the inhibition of multiple GTPases.  This is 
also true for the CA GTPases, which possess much higher affinity for their effectors and 
GAPs than wild-type GTPases (Burridge and Wennerberg, 2004; Owen et al., 2000; 
Wennerberg and Der, 2004). Consequently, the results of experiments using DN or CA 
GTPases are at times contradictory and often difficult to interpret. 
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Alternate methods to control Rho GTPase activity 
Besides direct mutation leading to altered protein activity, methods to modulate 
the activity of a single GTPase to study its specific function have included the use of 
siRNA and the development of small molecule or peptide inhibitors.  Unfortunately, the 
reduction of the levels of one Rho GTPase has been observed in some systems to result in 
the compensatory overexpression of other Rho GTPase family members (Bielek et al., 
2009).  In addition, due to the high homology between the family members, it is very 
difficult to design small molecule inhibitors that will target only one family member and 
to date very few have been developed.  One approach that was taken was the design of, or 
screening for, small molecules or peptides that would block interactions with GEFs, thus 
blocking activation.  The first reported small molecule inhibitor of Rac1, NSC23766 
(Gao et al., 2004) binds in a GEF recognition groove on Rac1, masking tryptophan 56, a 
residue that is a critical factor for selective binding of Rac1 specific GEFs Trio and 
Tiam1 (Gao et al., 2001)   However, this small molecule does not block activation by all 
GEFs, as the GEF Vav1 can still activate Rac1 in the presence of NSC23766.  A 
polypeptide derived from Rac1 containing tryptophan 56 has also been shown to 
specifically inhibit Rac1:GEF binding (Gao et al., 2001).  Additionally, the peptide Trio 
Inhibitory Peptide alpha (TRIP) inhibits RhoA activation by specifically targeting and 
binding to the RhoA-specific GEF domain of TRIO-GEFD2 (Schmidt et al., 2002).  
However, by design this inhibitor impacts RhoA activation by only a single GEF.  The 
minimum Cdc42-binding domain of the Cdc42 specific tyrosine kinase ACK1 (ACK42) 
has also been shown to bind to GTP-Cdc42 and block interaction with its effector 
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proteins (Nur et al., 1999).  This effector domain approach is highly specific to Cdc42 
inhibition.  However like many of these approaches it does not allow for spatial 
resolution of the achieved inhibition. 
The  small molecule inhibitor EHT1864 functions in a slightly different manner to 
inhibit Rho GTPases.  EHT 1864 inactivates Rho GTPases by causing nucleotide release 
(Shutes et al., 2007).  However EHT 1864 inhibition is not selective; it possesses activity 
towards multiple family members including Rac1, Rac1b, Rac2 and Rac3.  
 Another approach that was developed was to target the effectors of the Rho 
GTPases directly.  Several small molecules have been generated that block the activity of 
an effector of RhoA, Rho kinase (ROCK).  These include the Rho kinase inhibitors 
fasudil (HA-1077), Y-27632, and H-1152 (Ikenoya et al., 2002; Nagumo et al., 2000; 
Uehata et al., 1997). However, at higher concentrations all of these small molecules can 
affect the activity of other kinases including PKC, PKA and MLCK (Ishizaki et al., 2000; 
Sasaki et al., 2002; Tamura et al., 2005; Uehata et al., 1997).  Furthermore, only a subset 
of the functions of RhoA will be impacted by the use of these inhibitors, since GTP-
RhoA can still interact with downstream effectors other than ROCK (Bishop and Hall, 
2000). 
 Modulation of the isoprenoid modifications, and thus localization, of Rho 
GTPases using small molecule inhibitors of the prenyltransferases (Basso et al., 2006; 
Sebti and Hamilton, 2000)  or cholesterol lowering statins (Riganti et al., 2008) have also 
been used to control Rho GTPase activity.  However, these types of approaches will 
impact all proteins that rely on these types of lipid modifications for proper localization 
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and function and can affect other processes as well (Budzyn et al., 2006; Chrissobolis and 
Sobey, 2006; Liao and Laufs, 2005; Rikitake and Liao, 2005). 
There are also several bacterial proteins that can be introduced into cells that 
modulate Rho GTPase activity.  One is the cytotoxic necrotizing factor 1 (CNF1) from 
Escherichia coli (Lerm et al., 1999; Schmidt et al., 1997).  CNF1 activates RhoA, Rac1 
and Cdc42 by deamidation of Q61, the residue essential for GTP hydrolysis.  Clostridium 
botulinum exoenzyme C3 and related transferases specifically inhibit RhoA, RhoB, and 
RhoC, but not Rac1 or Cdc42 by ADP-ribosylating the GTPase on asparagine 41 in the 
effector binding domain (Aktories and Koch, 1997; Just et al., 1992; Sekine et al., 1989).  
Clostridium difficile toxins A and B glucosylate RhoA, Rac1, and Cdc42 on threonine 35, 
a residue that participates in the coordination of Mg2+ (Just et al., 1995a; Just et al., 
1995b).  Clostridium sordellii’s lethal toxin (LT) glucosylates Rac1 and Cdc42 but not 
RhoA, but it also can modify Ras proteins as well (Just et al., 1996; Popoff et al., 1996).  
Yersinia pseudotuberculosis cytotoxin YopE exhibits GAP activity towards RhoA, Rac1 
and Cdc42, increasing the rate at which they hydrolyze GTP to GDP and inactivating 
them (Von Pawel-Rammingen et al., 2000). 
Overall, all of the methods described above have been very useful in investigating 
the different roles of the Rho GTPase family members.  However, they are all limited in 
either their specificity and/or the degree to which they block an interaction or activity.  
Furthermore, they all lack spatial, and in some cases also temporal, resolution. 
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Techniques to observe Rho GTPase activity 
Other methods to study Rho GTPases have involved the development of tools to 
detect GTPase activation states. It is important to remember that traditional tools that 
allow for visualization of protein localization will not differentiate between the active and 
inactive forms of the GTPases. 
 One method used to assess the activation state of Rho GTPases is the pulldown of 
active GTPase with effector binding domains.  While the use of effector domains to pull 
down active GTPase from whole cell lysate of synchronized cell populations can provide 
a temporal assessment of GTPase activation state, it does not discriminate spatially and 
furthermore, its yields can be inefficient (Kimura et al., 2000).  Also, the time-scale 
resolution of this type of assay may not reflect the rapid activation events actually 
occurring.  In addition, certain methods of cell cycle synchronization can actually 
influence GTP-RhoA and GTP-Rac1 levels (Ren et al., 1999; Waterman-Storer et al., 
1999), potentially altering the timing and dynamics of the process being studied. 
 One simple method that has been employed to visualize Rho GTPase activation is 
the use of effector binding domains fused to fluorescent proteins (Figure 5-2A).  Thus, 
the fluorescently tagged binding domain, upon expression in cells, will translocate to 
areas where active Rho GTPases are located.  This method has, for example, been used 
successfully to visualize the dynamic patterns of RhoA and Cdc42 activation during 
wound healing in a Xenopus embryo (Benink and Bement, 2005).  Unfortunately, 
because many effectors can interact with multiple Rho GTPase family members, tools of 
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this type may actually report on the activation of multiple GTPases (Benard et al., 1999; 
Ren et al., 1999). 
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Figure 5-2.  Biosensors to detect Rho GTPase activation.  A).  GFP-tagged Rho 
effector binding domain (RBD) interacts specifically with endogenous GTP loaded active 
Rho GTPase.  B).  FRET occurs when a dye (red circle) labeled RBD interacts with GFP-
tagged GTP loaded active Rho GTPase.  C). and D).  FRET occurs upon interaction 
between CFP and YFP when an RBD and Rho GTPase either C). sandwiched between 
them, or D). fused to the termini of each, bind one another upon GTP binding and 
activation.  E).  FRET is relieved between CFP and YFP upon binding of the RBD 
sandwiched between them to endogenous GTP bound active Rho GTPase.  F).  
Solvatochromic-dye-based sensor.  The red star represents the solvatochromatic dye on 
the RBD, which exhibits increased fluorescence intensity upon binding to GTP loaded 
active Rho GTPase.  The black C-terminal extension on the GTPases and CFP in C).  
represents the prenyl modification. (Adapted from Pertz O.,  J. Cell Sci., 2010; 123: 
1841-1850.) 
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Another method that was developed relied on a fluorescence resonance energy 
transfer (FRET) based approach, where an effector was labeled with the cysteine-
selective iodoacetamide dye Alexa 546 on an introduced cysteine and injected into cells 
expressing a Rho GTPase tagged with green fluorescent protein (GFP) (Figure 5-2B).  
Thus, once the GTPase became active and bound the effector, FRET could occur between 
the dye and fluorescent protein and report on the GTPase’s activation (Kraynov et al., 
2000).  A similar experiment was conducted with genetically encoded yellow and cyan 
fluorescent protein (YFP and CFP) tagged GTPase and effector (Kraynov et al., 2000).  
Unfortunately, the fact that acceptor and donor fluorophores are on separate proteins, 
which may be localized differently in the cell, means that analyzing these type of 
experiment is complicated.   
FRET-based probes modeled after Ras and interacting chimeric unit (Raichu) 
(Itoh et al., 2002; Mochizuki et al., 2001; Seth et al., 2003)  have also been developed to 
detect activation of Rho GTPases in cells.  One such probe design consisted of an effector 
domain and its respective GTPase sandwiched between two fluorescent proteins, such 
that upon GTP binding and interaction of the GTPase and effector domain, FRET occurs 
and the emission ratios shift (Figure 5-2C) (Itoh et al., 2002; Yoshizaki et al., 2003).  
Prenylation of this probe was accomplished by appending the C-terminal polybasic 
CAAX sequence of the GTPase onto one of the fluorescent flanking proteins.  However, 
this means that the fusion is targeted constitutively to the membrane and regulation by 
RhoGDI proteins is prevented. 
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To address the lack of regulation by RhoGDIs and the constitutive membrane 
localization, an alternate probe type was designed where the two fluorescent proteins 
were sandwiched between the effector binding domain and the Rho GTPase (Figure 5-
2D).  This left the C-terminus of the GTPase free to be posttranslationally modified 
(Pertz et al., 2006). In general however, Raichu based probes are by design much bulkier 
than the GTPase alone and may not behave exactly as the endogenous GTPase would.   
Another probe design addressed prenylation by sandwiching only the effector 
binding domain between the two fluorescent proteins (Figure 5-2E) (Itoh et al., 2002; 
Yoshizaki et al., 2003).  Thus in solution, the two fluorescent proteins undergo FRET due 
to their close proximity.  However, upon binding of activated endogenous GTPase, a 
conformational change in the effector molecule occurs, relieving the interaction between 
the two fluorescent proteins and resulting in a loss of FRET.   Another non-FRET based 
approach to visualize Rho GTPase activation relied on a solvatochromatic dye fused to an 
effector binding domain (Figure 5-2F) (Nalbant et al., 2004).  In this case, the change in 
solvent polarity upon binding of the labeled effector binding domain to an activated 
GTPase resulted in an increase in fluorescence intensity.  However, much like effector 
binding domains tagged with a singe fluorescent protein, both of these types of probe 
designs may actually report on the activation of multiple Rho GTPase family members. 
The Rho GTPases are involved in a wide variety of highly divergent processes in 
the cell, many of which require the polarized localization of cellular substituents at 
specific times.  This in turn necessitates the tight regulation of the Rho GTPases and the 
numerous proteins that control their state of activation. In order to explore the regulation 
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of specific Rho GTPases and their regulatory components, as well as the spatial and 
temporal aspects of their activation in processes such as cell division, spatiotemporal 
control of their activation is critical.  However, because of limitations inherent to the 
current methodology for studying Rho GTPases, definitive correlations between specific 
functions and phenotypes are difficult.  Tools that can control individual GTPase 
activation states at specific intracellular cites and at specific times during the cell cycle 
could clarify the question of the roles the GTPases play in cell division, as well as in 
many other processes. 
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CHAPTER VI: Leveraging a Small-Molecule Modification to Enable the 
Photoactivation of Rho GTPases 
Introduction 
 Control of both the timing and location of protein activation is essential for cell 
growth and movement. One of the key ways in which cells accomplish this control is 
through the use of molecular switches known as Rho GTPases. When loaded with GTP, 
these proteins are activated and can bind to effector proteins that activate cellular 
responses (Figure 6-1). Subsequent hydrolysis of GTP to GDP returns the GTPase to the 
inactive GDP-bound state. The location of this molecular switch, and the timing of its 
activation, determines where and when cellular machinery is recruited to perform a 
specific biological function. Inappropriate activation of Rho GTPases alters this 
spatiotemporal control and is found to occur in many human diseases including cancer, 
hypertension, diabetes, asthma, pathogenic infection, and numerous neurological 
disorders (Boettner and Van Aelst, 2002). 
 
 98 
 
 
 
Figure 6-1.  Using photolabile small molecules to control Rho GTPase activity.  A) 
Exchange of GTP for GDP causes Rho GTPases to undergo a conformational change that 
allows them to interact with effector proteins and activate cellular responses.  B) 
Alkylation of the endogenous Cys18 in the nucleotide binding pocket of GTPases with a 
small-molecule photocage should prevent GTP binding and thus effector binding. C) 
Irradiation with UV light should remove the photocage, restoring Cys18 and allowing the 
GTPase to adopt the active conformation. 
 
 
 Traditionally, GTPase functions in living cells have been studied by the 
overexpression or microinjection of mutant forms of the proteins (Nobes and Hall, 1995). 
Constitutively active mutants cannot hydrolyze GTP, and thus remain perpetually in an 
active state. Dominant negative mutants inhibit the activation of endogenous GTPases, 
while fast-cycling mutants can cycle between active and inactive states independently of 
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cellular regulation (Lin et al., 1999). The use of these mutants has yielded considerable 
insight into the roles of Rho GTPases in different cellular processes. However, this type 
of approach lacks the spatial and temporal control needed to dissect the individual roles 
of specific GTPases at different subcellular locations and times during the cell cycle. In 
an effort to overcome this limitation, we have developed a general approach to control 
Rho GTPase activation with light (Leung et al., 2008). 
 As discussed, photoactivatable (“photocaged”) small molecules have been widely 
used to affect the rapid release of an active species at a defined location and time (Ellis-
Davies, 2007; Leung et al., 2008). Proteins have been photocaged by unnatural amino 
acid mutagenesis approaches (Chen et al., 2009; Edwards et al., 2009), the use of 
phytochrome fusion proteins (Leung et al., 2008), and by direct covalent modification 
with photolabile small molecules (Lee et al., 2009). In vitro modification followed by 
loading into live cells has successfully been used to allow spatial and temporal control of 
cellular protein activity. Notable examples include PKA (Curley and Lawrence, 1998a), 
cofilin (Ghosh et al., 2002), and Smad2 (Hahn and Muir, 2004). Nonetheless, the 
modification, purification, and selective functional disruption of photocaged proteins 
remains challenging. To begin to address these challenges, we took advantage of the 
wealth of structural information available for the Rho GTPase family.  
 Most Rho GTPases contain a cysteine residue within the nucleotide binding 
pocket. We predicted that alkylation of this cysteine in the Rho GTPase Cdc42 would 
block the ability of GTP to bind and activate Cdc42 (Figure 6-1B) and that subsequent 
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irradiation with long-wave UV light would release this small molecule, restoring Cdc42’s 
GTP-binding capacity (Figure 6-1C).  
 
Materials and Methods 
 
Materials 
Chemicals for synthesis were from Aldrich unless otherwise noted. Amino-
mPEG5K was from Fluka. NMR spectra were recorded on a Varian Mercury 400 MHz 
NMR. Mass spectra were acquired at the UMass Proteomic Mass Spectrometry Lab on a 
Waters QTof Premier mass spectrometer (small molecule exact mass) or Thermo 
Scientific LCQ and LTQ ion trap mass spectrometers (protein mass spectra). Compound 
1 (2-bromo-2-(2-nitrophenyl)acetic acid) was synthesized as previously described (Chang 
et al., 1995). The HaloTag ligand, 2-[2-(6-Chlorohexyloxy)-ethoxy]-ethylamine, was 
synthesized as previously described (Zhang et al., 2006). Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). Buffer exchange was performed 
using Zeba gel-filtration columns (Pierce). Immobilized glutathione (Thermo Scientific) 
was used for both GST-tagged protein purification and pull-down experiments. Unless 
otherwise stated, all protein purification steps we carried out at 4˚C. 
 
Synthesis of 2-Bromo-N,N-diethyl-2-(2-nitrophenyl)-acetamide (2) 
  To a solution of 1 (0.2 mmol, 52 mg) in dichloromethane (2 mL) was added DIC 
(46.5 mL, 0.3 mmol) and diethylamine (31 mL, 0.3 mmol). The solution was left at RT 
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for 3h, then directly purified by flash chromatography (0-25% ethyl acetate in hexanes). 
Yield 27.7 mg clear film (44%). 1H-NMR (400 MHz, CDCl3): d 8.09 (dd, 1H, J = 1.6, 
8.4 Hz), 7.88 (dd, 1H, J = 1.2, 8 Hz), 7.62 (dt, 1H, J = 1.6, 8 Hz), 7.41 (dt, 1H, J = 1.2, 8 
Hz), 6.27 (s, 1H), 3.58-3.29 (m, 4H), 1.27 (t, 3H, J = 7.6 Hz), 1.07 (t, 3H, J = 7.6Hz).  
13C-NMR (100 MHz, CDCl3): d 166.20, 147.69, 135.08, 133.82, 131.98, 129.64, 124.61, 
42.99, 41.40, 41.29, 14.02, 12.50. Calculated for C12H16N2O3Br: 315.0344, found: 
315.0374. 
 
Synthesis of BNPA-mPEG5K (3) 
 To a solution of amino-mPEG5K (100 mg, ~ 0.17 mmol amine/g) and 1 (26 mg, 
0.1 mmol) in dichloromethane (1 mL) was added DIC (15.5 mL, 0.1 mmol). The solution 
was incubated overnight at RT, then diluted into 50 ml of 2-propanol. The solution was 
chilled on ice for 30 minutes, during which time the polymer precipitated. The solution 
was filtered and washed with room-temperature 2-propanol. Residual solvent was 
removed in vacuo to afford a white powder. 1H-NMR (400 MHz, CDCl3): d 7.98 (dd, 1H, 
J = 1.6, 8.4 Hz), 7.88 (dd, 1H, J = 1.2, 8 Hz), 7.65 (dt, 1H, J = 1.2, 8 Hz), 7.50 (dt, 1H, J 
= 1.2, 8 Hz), 6.10 (s, 1H), 3.63 (s, >400H), 3.37 (s, 3.45H). Small apparent peaks near the 
polymer resonance at 3.63 were difficult to resolve. The BNPA substitution of the 
polymer was estimated to be 82% based on the relative integration of the well-resolved 
mPEG methoxy peak at 3.37 ppm and the benzylic methine proton at 6.10 ppm. 
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Synthesis of 2-Bromo-N-[2-[2-(6-chlorohexyloxy)-ethoxy]-ethyl] -2-(2-nitrophenyl)-
acetamide (BNPA-HT, 4) 
 To a solution of 1 (52 mg, 0.2 mmol) in dichloromethane (1 mL) was added 2-[2-
(6-Chlorohexyloxy)-ethoxy]-ethylamine (45 mg, 0.24 mmol) followed by DIC (39 mL, 
0.25 mmol). The solution was stirred overnight at RT and purified by flash 
chromatography (0-50% ethyl acetate in hexanes). Yield 39 mg (42%). 1H-NMR (400 
MHz, CDCl3): d 8.00 (dd, 1H, J = 1.6, 8.4 Hz), 7.84 (dd, 1H, J = 1.2, 8 Hz), 7.66 (dt, 1H, 
J = 1.2, 8 Hz), 7.50 (dt, 1H, J = 1.6, 8 Hz), 7.17 (br s, 1H), 6.10 (s, 1H), 3.68-3.5 (m, 8H), 
3.53 (t, 2H, J = 6.8 Hz), 3.49 (t, 2H, J = 6.8 Hz), 1.78 (m, 2H), 1.62 (m, 2H), 1.5-1.35 (m, 
4H). 13C-NMR (100 MHz, CDCl3): d 166.34, 147.89, 134.05, 132.75, 132.55, 130.04, 
125.28, 71.56, 70.72, 70.31, 69.55, 45.31, 45.01, 40.54, 32.74, 29.70, 26.93, 25.66. 
Calculated for C18H27BrClN2O5: 465.0792, found: 465.0743. 
 
Plasmid constructs 
Mutant proteins were created using the Quickchange site-directed mutagenesis kit 
(Stratagene). Truncated Cdc42 F28L/C188S was made by PCR of the full-length gene 
with the primers gaatggatccatgcagacaattaagtgtgttgttgtgg and 
gaacgaattctcaagaccgcggctcttcttcggttctgg.  This PCR product was then digested with 
BamHI and EcoRI and ligated into the corresponding sites in pGEX6P-1.  The F28L 
point mutation was introduced with the primers cctacacaacaaacaaactgccatcggaatatgtaccg 
and cggtacatattccgatggcagtttgtttgttgtgtagg. The C18S mutation was introduced using the 
primers gctgttggtaaaacatctctcctgatatcctac and gtaggatatcaggagagatgttttaccaacagc. 
 103 
Truncated Rac1 F28L/C189S was made by PCR of the full-length gene with primers 
gaatggatccatgcaggccatcaagtgtgtggtg and gaacgaattctcaagattttctcttcctcttcttcacgggag.  This 
PCR product was also digested with BamHI and EcoRI, and ligated into pGEX6P-1.  The 
F28L point mutation was introduced into the resulting plasmid with primers 
gttacacaaccaatgcactgcctggagaatatatccctac and gtagggatatattctccaggcagtgcattggttgtgtaac.  
 
Protein expression 
 Cdc42 F28L/C188S (residues 1-188), Rac1 F28L/C189S (residues 1-189) and the 
p21-activated kinase binding domain (PBD) (residues 66-150) were expressed as GST 
fusion proteins from the vector pGEX6P-1 in the BL21(DE3) E. coli strain as previously 
described (Bhunia and Miller, 2007).  HaloTag (Promega) was expressed as a His6 fusion 
protein from the vector pET28 in the BL21(DE3) pLysS E. coli strain. Cells were grown 
at 37˚C until the OD600 reached 0.8, then induced with 0.1 mM IPTG and incubated at 
20˚C overnight.  Cells were pelleted at 5000 rpm in a Sorvall 2C3C Plus centrifuge 
(H600A rotor) at 4˚C for 10 minutes, then flash frozen in liquid nitrogen and used 
immediately or stored at -80˚C. 
 
GTPase and PBD purification 
 E. coli cell pellets from one liter of culture were thawed on ice, resuspended in 25 
ml Lysis Buffer (50 mM Tris or HEPES pH 7.4, 500 mM NaCl, and 0.5% Tween-20) 
containing 1 mM PMSF and disrupted by sonification (Branson Sonifier). Dithiothreitol 
(DTT) was added at 10 mM and the resulting cell lysate was clarified by centrifugation at 
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35K rpm in a Beckman 50.2Ti rotor for 1 hour.  The supernatant was batch-bound to 
immobilized glutathione for 1h at 4˚C, and then the beads were washed with Lysis Buffer 
containing 10 mM DTT followed by Wash Buffer (50 mM Tris pH 8.1, 250 mM NaCl 
and 10 mM DTT).   
For Cdc42 and Rac1, the beads were then incubated with Nucleotide Removal 
Buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM TCEP, and 20 mM EDTA) and finally 
washed with Storage Buffer (50 mM HEPES pH 7.4, 50 mM NaCl, 1 mM TCEP, and 5 
mM EDTA).  Twenty units of PreScission Protease (GE Healthcare) were added and 
incubation continued overnight at 4˚C to cleave the GST fusion and elute the untagged 
GTPase. 
For PBD, 3 mg/mL reduced glutathione in Wash Buffer was used to elute the 
GST-tagged PBD, which was then dialyzed against 50 mM Tris pH 7.4, 150 mM NaCl, 1 
mM TCEP, and 1 mM EDTA.   
 
HaloTag purification 
 E. coli cell pellets were thawed on ice, resuspended in 50 mM NaPhos pH 7.8, 
500 mM NaCl, 10 mM imidazole, and 0.1% Tween-20 containing 0.2 mM PMSF and 
disrupted by sonification. BME was added at 5 mM and the resulting cell lysate was 
centrifuged at 35K rpm in a Beckman 50.2 Ti rotor for 1 hour at 4˚C.  The clarified 
supernatant was batch-bound to Talon resin (BD Biosciences) for 1 hour at 4˚C.  The 
beads were washed with 50 mM NaPhos pH 7.8, 500 mM NaCl, 30 mM imidazole and 5 
mM BME.   The His6 HaloTag was eluted with 50 mM NaPhos pH 7.8, 500 mM NaCl, 
 105 
300 mM imidazole and 5 mM BME, then dialyzed against 50 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM TCEP, and 1 mM EDTA.   
 
Small molecule modification of Cdc42 
 Cdc42 (1-188, F28L/ C188S) was expressed and purified as previously described 
(Bhunia and Miller, 2007).  The GTPase was made nucleotide-free by incubation with 20 
mM EDTA for 15-30 min at RT, and the unbound nucleotide removed by passage over 
two sequential Zeba gel-filtration columns (Pierce) equilibrated with 50 mM HEPES pH 
7.4, 50 mM NaCl, and 5 mM EDTA. Ten equivalents of the small molecule photocage 
were then added and allowed to react in the dark at 22°C for 3h with shaking at 300 rpm 
(Eppendorf Thermomixer). Unreacted alkylating agent was removed by passage over a 
Zeba column equilibrated with 50 mM Tris pH 7.4, 150 mM NaCl, 1mM TCEP, and 1 
mM EDTA.  
 
Recruitment of HaloTag protein to Cdc42 modified with 4 
 Cdc42 that had been alkylated with 4 was incubated with 0.3-0.5 eq of purified 
HaloTag protein at 22°C in the dark for 1h with shaking at 300 rpm. The HaloTag-
modified GTPase was purified by FPLC (AKTA) on a MonoQ ion-exchange column (GE 
Healthcare). The unmodified GTPase and the HaloTag-modified GTPase eluted as 
separate peaks on a linear gradient of 0-1M NaCl over 25 min at a flow rate of 1 ml/min. 
The purity of the fractions was assessed by SDS-PAGE with Coomassie staining. 
Purified HaloTag-modified GTPase was used directly for photolysis reactions and 
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effector pull-down assays. The final buffer composition was determined to be 50 mM 
Tris pH 7.4, 300 mM NaCl, 1 mM DTT and 1 mM EDTA. 
 
GTPase effector pulldown assay 
 The ability of each GTPase to adopt an active conformation was assessed using a 
modification of the standard GST-PBD pulldown assay (Benard et al., 1999). GTPases 
were loaded with 10 mM MgCl2 and 4 molar equivalents of either GDP or GTPγS for 
15-30 min at room temperature. PBD was loaded onto immobilized glutathione at 4 
molar equivalents relative to the concentration of the GTPase for 30 minutes, and the 
nucleotide-loaded GTPase was then added.  The proteins were allowed to interact at 4˚C 
for 30 minutes, and then the unbound fraction was removed.  The beads were washed 
twice with 8 volumes of 50 mM Tris pH 7.4, 150 mM NaCl, 2 mM MgCl2, 1 mM TCEP, 
and 0.1% Triton X-100, and then 4 volumes of 40 mM Tris pH 7.4, 100 mM NaCl, 20 
mM MgCl2 and 1 mM TCEP. The bound fraction was eluted from the beads by boiling in 
SDS-PAGE gel loading buffer.  The bound and unbound fractions for each nucleotide 
state were compared by SDS-PAGE with Coomassie staining. 
 
Fluorescence Polarization Assay 
 The ability of GTP to bind the GTPase was evaluated by a fluorescence 
polarization assay, performed in triplicate in a 384-well plate. Each well contained 30 L 
of 50 mM HEPES pH 7.4, 150 mM NaCl, 20 mM MgCl2 and 1 mM TCEP buffer alone, 
or with 400 nM of either purified His6HaloTag, purified apo-Cdc42, Cdc42 preincubated 
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with 5 mM GTPS, FPLC-purified Cdc42-4-HT, or FPLC-purified Cdc42-4-HT that had 
been uncaged for 10 minutes at 350 nm as described above. BODIPY-FL-GTP 
(Invitrogen) was added to each well at a final concentration of 100 nM immediately 
before reading.  The fluorescence polarization was measured in a PerkinElmer Victor3 
1420 Multilabel Counter with a 480 nm CW lamp filter and a 535 nm emission filter. 
Measurements were taken for 1.0 second with 5 repeats per well.  
 
Photolysis reaction 
 FPLC-purified HaloTag-modified GTPase was placed in a 384-well plate that had 
been preincubated at -20˚C, and irradiated with a 450W xenon arc lamp (Oriel 66021 
lamp housing) through an IR cut-off filter and a 350 nm bandpass filter for times ranging 
from 10 seconds to 30 minutes. 
 
Results and Discussion 
  To test the hypothesis that we could modify and block nucleotide binding in Rho 
GTPases in a light sensitive manner, we attempted to alkylate cysteine 18 in a fast-
cycling Cdc42 mutant (1-188, F28L/C188S). However, using previously reported 
photocages such as 2-bromo-2-(2-nitrophenyl)acetic acid 1 (Chang et al., 1995) (Scheme 
6-1), we found that we could not completely separate the modified protein from the 
unmodified protein and that alkylation of this cysteine failed to completely prevent the 
ability of GTP to activate Cdc42 as determined by an effector pulldown assay (Figure 6-
2).  Because any contaminating uncaged protein or residual activity of the caged protein 
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would compromise the spatial and temporal control afforded by photocaging, it is 
important that the caged protein be purified and inactive.  
 
 
              
 
 
 
Scheme 6-1. Photocages used in CHAPTER VI. 2-bromo-2-(2-nitrophenyl)acetic acid 
(1) is widely used as a photocage, but fails to block Cdc42 activation by GTP. Bulkier 
derivatives such as 2 similarly fail to block Cdc42 activation. The mPEG polymer 3 did 
not alkylate cysteine 18. Photocage 4 blocks Cdc42 activation only after recruitment of 
HaloTag to its ligand. 
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Figure 6-2.  Effector binding domain assay.  Top).  Alkylation with 1 alone does not 
prevent the GTP-dependent conformational change of Cdc42 necessary for activation of 
Cdc42 or its ability to bind to GST-PBD (Effector). Bottom).  In a GST-PBD pulldown 
assay, both unmodified Cdc42 and Cdc42 modified with 1 bind the PBD effector in the 
presence of the non-hydrolyzable GTP analog GTPS.  As expected, neither bind PBD in 
the presence of GDP.  UB = unbound protein; B = bound protein. 
 
 
 
 Since previously reported photocages failed to block Cdc42 activation, we 
synthesized novel photocages with additional steric bulk (Marriott et al., 2003). However, 
these molecules either failed to block Cdc42 activation (e.g., 2) or failed to alkylate 
cysteine 18 (3). The apparent plasticity of the nucleotide binding pocket is surprising, and 
underscores the difficulty in photocaging protein functions, even when structural 
information is available. To surmount this obstacle, we developed a new general strategy 
to photocage protein interactions by leveraging a small molecule protein modification 
into a large one. 
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 We report here a new photocage (4) that contains a ligand for the protein HaloTag 
(Scheme 6-1). HaloTag is a 33 kDa mutant haloalkane dehalogenase that specifically 
forms a covalent bond with the HaloTag ligand (Los and Wood, 2007).  After alkylation 
of Cdc42 with 4, we incubated the modified protein with purified recombinant HaloTag. 
The bioorthogonality of this interaction allows the specific recruitment of HaloTag only 
to protein modified with 4. The resulting caged fusion protein Cdc42-4-HT is well 
resolved from both Cdc42 and HaloTag on SDS-PAGE (Figure 6-3B, lane 3). Moreover, 
the large negative charge of HaloTag greatly facilitates its purification by ion-exchange 
chromatography. Importantly, this property allowed us to completely separate the caged 
protein from the unmodified protein. Subsequent irradiation with long-wave UV light 
(350 nm, 10 sec, 450W Xe arc lamp) readily releases Cdc42 from Cdc42-4-HT (Figure 6-
3B, lane 4).  
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Figure 6-3. Photocaging of Cdc42. A) modification with 4 alone fails to prevent GTP-
induced activation of Cdc42, but upon recruitment of HaloTag (HT), the resulting fusion 
protein can no longer bind effector in a GTP-dependent manner. Photolytic uncaging of 
the Cdc42-4-HT fusion at 350 nm liberates Cdc42, which can again bind effector in a 
GTP-dependent manner. B) Lane 1: Cdc42; Lane 2: HT; Lane 3: Cdc42-4-HT; Lane 4: 
Cdc42-4-HT after irradiation at 350 nm.  C) In a GST-PBD pulldown assay, only Cdc42-
4-HT fails to bind the PBD effector in the presence of the non-hydrolyzable GTP analog 
GTPS. UB = unbound protein; B = bound protein. 
 
 
 
The recruitment of HaloTag to the nucleotide binding site of Cdc42 effectively 
leverages 4, a small molecule modification, into a large 33 kDa protein modification 
(Figure 6-3A). Unlike the small molecule photocages – including 4 alone – we found that 
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the recruitment of HaloTag prevented the GTP-induced activation of Cdc42 as 
determined by the pull-down assay (Figure 6-3). 
 Cdc42 is activated and binds to the p21-binding domain (PBD) of its effector p21-
activated kinase (PAK) only in the GTP-bound form (Figure 6-3C) (Benard et al., 1999). 
Use of the non-hydrolyzable GTP analog, GTPS, prevents any hydrolysis to the inactive 
GDP-bound form during this binding assay. Alkylation of the fast-cycling mutant of 
Cdc42 with 4 alone fails to prevent activation by GTPS. In contrast, the recruitment of 
HaloTag to Cdc42-4 prevents effector binding (Figure 6-3C) due to an inability to bind 
nucleotide, as assessed by a fluorescence polarization assay (Figure 6-4).  Specifically, 
the degree of polarized light measured in buffer containing BODIPY-FL-GTP alone (1), 
or BODIPY-FL-GTP with the HaloTag protein (2) or Cdc42 protein with 5 mM GTPS 
competitor (4), was relatively low.  These low levels indicate that the BODIPY-FL-GTP 
is rotating rapidly and free in solution, thus not associating with protein present.  
However, the degree of polarized light measured in buffer containing BODIPY-FL-GTP 
and Apo-Cdc42 protein (3) is relatively high, indicating that the protein has bound 
BODIPY-FL-GTP.  There is a relatively low level of polarized light measured in buffer 
with BODIPY-FL-GTP and caged Cdc42-4-HT fusion (5), indicating that the Cdc42-4-
HT fusion does not bind BODIPY-FL-GTP.   Uncaging Cdc42 through photolysis of 
Cdc42-4-HT restores its ability to bind BODIPY-FL-GTP as evidenced by the high 
fluorescent polarization signal measured with it in buffer with BODIPY-FL-GTP (6). 
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We postulate that the HaloTag protein forces the photocage to thread straight through the 
nucleotide binding site, preventing the binding of GTP. In contrast, small molecule 
modifications alone are more flexible, and could potentially adjust to accommodate GTP 
binding (Figure 6-3A). 
 
 
 
 
Figure 6-4. Fluorescence polarization assay.  The degree of polarization of light was 
measured in buffer containing 1) BODIPY-FL-GTP alone, or with BODIPY-FL-GTP and 
2) HaloTag protein, 3) Apo-Cdc42 protein, 4) Apo-Cdc42 protein with 5 mM GTPS 
competitor, 5) caged Cdc42-4-HT fusion, and 6) uncaged Cdc42 from photolysis of 
Cdc42-4-HT. Apo-Cdc42 and uncaged Cdc42 bind BODIPY-FL-GTP as evidenced by 
the high fluorescent polarization signal, while HaloTag, apo-Cdc42 with a 50-fold excess 
of GTPS competitor, and Cdc42-4-HT do not. 
 
 
 
 Irradiation with long-wave UV light (350 nm) readily cleaves the photolabile 
linkage in Cdc42-4-HT, unmasking cysteine 18 and restoring the activated Cdc42 fast-
cycling mutant protein  (Figure 6-3). Notably, the nitroso-ketone photoproduct (Figure 6-
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1C) remains attached to HaloTag and does not reattach to Cdc42, allowing them to 
migrate as separate species when analyzed by SDS-PAGE (Figure 6-3b, lane 4; Figure 6-
5). The uncaged Cdc42 behaves identically to unmodified Cdc42, showing the same 
nucleotide-dependent binding of PBD (Figure 6-3C). 
 
 
 
 
Figure 6-5.  Uncaging reaction.  Irradiation with long-wave UV light (350 nm) uncages 
Cdc42-4-HT, releasing HaloTag and Cdc42.  Substantial uncaging occurs in less than 10 
seconds and is mostly complete between 2 and 5 minutes. 
 
 
 Cdc42 (1-188, F28L/C188S) contains five cysteine residues. Modification of 
cysteine 18 in the nucleotide binding site is quite specific, and is completely blocked by 
mutation of cysteine 18 to serine. Moreover, alkylation of cysteine 18 can be specifically 
blocked by pre-incubation with GDP (Figure 6-6).  
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Figure 6-6. Specificity of modification and HaloTag recruitment. Alkylation of Cdc42 
with 4 allowed the recruitment of a single HaloTag to Cdc42. Alkylation with 4 and 
subsequent recruitment of HaloTag was completely prevented by pre-incubation with 
GDP or mutation of cysteine 18 to serine: a) alkylation of Cdc42 with 4 followed by 
incubation with HaloTag results in the formation of the fusion product Cdc42-4-HT only 
when the protein is nucleotide-free and contains cysteine 18; b) nucleotide-free Cdc42 is 
modified only once by 4; c) incubation with GDP prevents alkylation with 4; d) mutation 
of cysteine 18 to serine prevents alkylation with 4. 
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Since most Rho GTPases contain a cysteine at this position in the nucleotide 
binding site, we anticipated that our strategy would be generalizable, allowing the 
construction of photoactivatable versions of other family members. Consistent with this 
assertion, we have found that the Rho GTPase Rac1 can be photocaged in the same 
manner as Cdc42, and that it also requires our leveraged recruitment method for 
successful photocaging (Figure 6-7). 
 
     
 
Figure 6-7.  Photocaging of Rac1.  An effector binding assay with PBD shows that 
modification with 4 alone does not prevent the ability of Rac1 to bind GTP and become 
active, but subsequent modification with the HaloTag protein does.  Irradiation at 350 nm 
uncages Rac1-4-HT and restores the ability of Rac1 to bind effector in the presence of 
GTP. In a GST-PBD pulldown assay, only Rac1-4-HT fails to bind the PBD effector in 
the presence of the non-hydrolyzable GTP analog GTPS. UB = unbound protein; B = 
bound protein 
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 In order to maximize protein expression levels and simplify purification, these 
studies were performed with bacterially-expressed GTPases that lack their C-terminal 
prenylation site. For future cell-based studies using microinjected protein, prenylated or 
prenylation-competent protein would be required for proper intracellular localization.
 The leveraged recruitment strategy described here greatly facilitates the 
preparation of photoactivatable proteins by allowing their separation from uncaged 
protein. While HaloTag was used in this work, in principle other protein labeling 
strategies could be employed. We anticipate that the larger steric footprint afforded by 
this leveraged recruitment strategy will be of general utility for improving the 
photocontrol of a variety of protein interactions that, like the Rho GTPases, are 
recalcitrant to inhibition by small molecule modifications alone. 
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CHAPTER VII: Efforts to introduce Caged Rho GTPases into cells 
Introduction 
 CHAPTER VI describes the ability to photocage the activity of the Rho GTPases 
Cdc42 and Rac1 using an ortho-nitrobenzyl photocage derivative functionalized with a 
ligand to allow for recruitment of the haloalkane dehalogenase HaloTag. This two-part 
modification system was sufficient to block GTP binding, and thus activation of these 
proteins in vitro.  However, in order to use this tool to investigate spatial and temporal 
activation requirements of these proteins in vivo, the caged protein must be introduced 
into cells. 
 The transfection of DNA into cells to allow for the expression or overexpression 
of proteins of interest has been widely used to study biological processes.  Techniques to 
deliver proteins into cells are less well established. Proteins have been introduced into 
cells in several manners including through microinjection, the use of protein transfection 
reagents, and by fusion to cell-penetrating peptides. 
 Microinjection, a technique where a glass micropipette is used to insert substances 
at a microscopic level into living cells, is a powerful technique and offers many 
advantages, including the ability to introduce a wide variety of molecular species into 
either the nucleus or cytoplasm.  It is not without its drawbacks however, as it can be 
difficult technically and it is physically invasive.  Also, because microinjection is 
performed on a cell-by-cell basis, it does not allow for large-scale biochemical assays.   
 Several protein transfection reagents are commercially available that can be used 
to introduce recombinant protein into a cell.  One of these, Chariot (ActivMotif), can be 
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used to deliver peptides, antibodies and proteins into cells.  Chariot is a peptide that 
forms a non-covalent complex with the peptide/protein species to be introduced, and 
facilitates entry into the cell via what has been suggested to be a non-endosomal based 
mechanism.  Upon cell entry, the Chariot peptide disassociates and a nuclear localization 
sequence localizes it to the nucleus, where it is degraded (Morris et al., 2001).  Another 
reagent, BioPORTER (Genlantis), is a mixture of cationic lipids that form a non-covalent 
complex with the protein to be introduced into the cell.  Once applied to cells, the 
complexes attach to the negatively charged cell surface and either 1) the BioPORTER 
lipids fuse with the plasma membrane, releasing the protein into the cell or 2) the 
complexes are internalized via endocytosis and the BioPORTER fuses with the 
endosomal membranes, translocating the protein into the cell in that manner (Zelphati et 
al., 2001). 
 Another method to introduce proteins into a cell is to genetically fuse a cell-
penetrating peptide (CPP), a short and typically cationic peptide, to the protein of interest 
to allow for its cellular uptake.  Some examples of CPPs are a peptide ( a.a.’s 48-60) from 
the HIV-1 protein Tat (Vives et al., 1997), the peptide penetratin ( a.a.’s 43-58) from the 
protein Antennapedia (Derossi et al., 1994),  and a peptide from the herpes virus protein 
VP22 (Kueltzo et al., 2000), as well as others.  Many of these CPPs possess an abundance 
of arginine residues that seem to play a role in the efficiency of cellular uptake (Kosuge 
et al., 2008; Thoren et al., 2003).  In fact, oligoarginines themselves have proved to be 
efficient CPPs (Futaki et al., 2001).   
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 There is considerable debate regarding the mechanism of cellular entry both by 
transfection and the use of CPPs.  Two of the proposed mechanisms of cellular entry are 
direct energy-independent penetration and endosomal uptake.  In direct energy-
independent penetration, whereby the protein tagged with the CPP translocates directly 
through the lipid bilayers of the plasma membrane, the introduced protein would be 
localized diffusely throughout the cell (Derossi et al., 1994; Takeuchi et al., 2006).  If 
uptake was endosomal, whereby a portion of the plasmid membrane envelops the CPP 
tagged proteins and buds off into the cytoplasm, the resulting localization would be to 
endosomal vesicles, from which the protein would need to be released (El-Andaloussi et 
al., 2006; Wadia et al., 2004).  It has been suggested that pre-incubation of a CPP-tagged 
protein with the hydrophobic counter-anion 4-(1-prenyl)-butyric acid (pyrenebutyrate) 
can help facilitate cellular uptake through non-endosomal pathways (Perret et al., 2005; 
Sakai and Matile, 2003; Wadia et al., 2004). Described here are attempts to employ 
several of the methods described above to introduce caged FC-Cdc42-HT into cells via a 
non-endosomal based pathway. 
 
Material and Methods 
Cell Culture 
HeLa cells were grown in a CO2 incubator at 37˚C with 5% CO2 and were 
cultured in Dulbecco's Modified Eagle Medium (DMEM) mixture (GIBCO) 
supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. 
Chinese hamster ovary-K1 (CHO-K1) cells were grown in a CO2 incubator at 37˚C with 
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5% CO2 and were cultured in F-12K Nutrient mixture (GIBCO) supplemented with 10% 
fetal bovine serum and 100 U/mL penicillin/streptomycin. 
 
Plasmid construction 
 The modified haloalkane dehalogenase HaloTag (HT-Promega) gene was PCR-
amplified and cloned into the BamH1 and Not1 sites of pET28a for bacterial expression.  
A polyarginine tag consisting of 9 arginines was introduced at C-terminus using the 
primer termed 9R C-terminus: 
gaacgcggccgcttaacggcgacggcgacggcgacggcgacggccggccagcccggggag.  HT protein tagged 
on the N-terminus with a polyarginine tag was not stable. 
 The O6-methylguanine-DNA methyltransferase (SNAP) gene was PCR-amplified 
and cloned into the Nde1 and EcoRI sites of pET28a for bacterial expression.  
Polyarginine tags consisting of 9 arginines were introduced at the N-and C-termini using 
the primers termed 9R N-terminus: 
gaatactagtcatatgcgtcgccgtcgccgtcgccgtcgccgtgacaaagattgcgaaatgaaac and 9R C-terminus: 
gaacgaattcttaacggcgacggcgacggcgacggcgacgggatcctggcgcgcctatacc. 
 
Protein preparation 
 Protein was prepared as previously described in CHAPTER VI. 
 
HT and SNAP labeling 
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Recombinant HT, polyarginine tagged HT, or polyarginine tagged SNAP proteins 
were incubated with one molar equivalent of tetramethylrhodamine (TMR) conjugated to 
the HaloTag reactive ligand (Promega) or DY-549 conjugated to the SNAP reactive 
ligand (New England BioLabs) for 1 hour at 22˚C in the dark with shaking at 300 rpm 
(Eppendorf Thermomixer).  Unreacted ligand was removed by passage over a Zeba 
column (Pierce) equilibrated with sterile Hanks Buffered Saline solution (HBSS). 
 
Western blotting 
 Following treatment with either Chariot or BioPORTER, cells were washed with 
PBS, trypsinized and pelleted at 1000 rpm speed in an A-4-62 rotor in an Eppendorf 
model 5810R centrifuge.  Cells were lysed in 300 L Mg2+ Lysis Buffer (25 mM HEPES 
pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 0.25% Na deoxycholate, 10% glycerol, 25 
mM NaF, 10 mM MgCl2 , 1 mM EDTA, 1 mM Na orthovanadate, 10 g/mL leupeptin, 
and 10 g/mL aprotinin) at 4˚C with spinning in the dark.  Lysates were pelleted at 10K 
rpm in an F45-24-11 rotor in an Eppendorf centrifuge model 5415D. Total protein 
concentration was determined using a bicinchoninic acid (BCA) protein assay.  Volumes 
of supernatant totaling 30 g total cellular protein were diluted with SDS-PAGE loading 
buffer containing 10 mM DTT, separated on a 12% polyacrylamide gel, and transferred 
to nitrocellulose membrane. A lane containing a load control equal to the total amount of 
protein loaded into cells was also included.  The membranes were blocked with blocking 
buffer (5% nonfat dry milk in PBS containing 0.2% Tween 20) overnight at 4˚C with 
shaking.  Mouse anti-Cdc42 (Santa Cruz) or rabbit anti-HaloTag antibody (Promega) in 
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blocking buffer was added at 1:200 and 1:1,000, respectively, at room temperature for 3 
hours.  The membranes were washed 3 times for ten minutes in PBS and then goat anti-
mouse or goat anti-rabbit horseradish peroxidase conjugated antibody (Promega) in 
blocking buffer was added at 1:3,000 and incubated for 30 minutes at room temperature.  
The membranes were washed 3 times for 5 minutes in PBS.  Horseradish peroxidase-
bound proteins were detected by chemiluminescence using SuperSignal West Dura 
chemiluminescent substrate (Thermo Scientific Pierce).  Membranes were imaged using a 
Fujifilm LAS-3000 CCD camera.  
 
Fluorescent microscopy 
Cells were examined on a Zeiss Axiovert 200 fluorescence microscope with a 
40X objective using a Hamamatsu ORCA-ER digital camera and excitation from an X-
Cite 120 light source through a Zeiss filter cube. 
 
Transfection with Chariot 
For analysis by Western blot: HeLa cells were seeded at 60-75% confluency in a 
100 mm plate in media supplemented with 10% fetal bovine serum without antibiotic. 
Chariot was resuspended as directed by the manufacturer and 50 L was added to 150 L 
sterile water per treatment type.  40 g of the caged Cdc42 F28L-HT protein was added 
to a final volume of 200 L sterile phosphate buffered saline (PBS).  The diluted Chariot 
and protein were mixed gently and the mixture was incubated at room temperature for 30 
minutes.  Cells were washed with PBS, the protein: Chariot mixture was added, followed 
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by 4.6 mL of serum free DMEM.  The cells were incubated at 37˚C for 1 hour and 
overlaid with 5 mL DMEM media supplemented with 10% fetal bovine serum and 100 
U/mL penicillin/streptomycin and incubated at 37˚C for 2 additional hours.  Following 
this incubation, the media was removed and cells were washed with PBS three times.   
 
Transfection with BioPORTER 
For analysis by Western blot: HeLa cells were seeded at 60-75% confluency in a 
100 mm plate in media supplemented with 10% fetal bovine serum without antibiotic. 40 
g of the caged Cdc42 F28L-HT protein was added to a final volume of 300 L sterile 
phosphate buffered saline (PBS).  100 L of the diluted protein was added to 35 L 
BioPORTER reagent in triplicate and after 5 minutes, the mixture was pipetted up and 
down and then vortexed gently.  After a 30-minute incubation, 400 L of serum free 
media was added to each tube.  Cells were washed with PBS and then overlaid with 3 mL 
serum free media followed by the 1.5 mL BioPORTER: protein mixture, and incubated at 
37˚C for 3 hours. 
For analysis by microscopy: HeLa cells were seeded at 60-75% confluency in a 
96-well plate in media supplemented with 10% fetal bovine serum without antibiotic.  
Two g of TMR labeled HT protein was added to a final volume of 40 L sterile HBSS, 
which was added to 10L of BioPORTER reagent. The mixture was pipetted up and 
down, incubated for 5 minutes, and then vortexed gently.  After a 30-minute incubation, 
500 L of serum free media was added.  Cells were washed with HBSS and then overlaid 
with 50 L serum free media followed by the 50 L BioPORTER: protein mixture, and 
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incubated at 37˚C for 3 hours. The media was removed and cells were washed 3 times 
with Opti-MEM (GIBCO) before imaging.  
   
CPP and Pyrenebutyrate 
For HT, HeLa cells were seeded at 60-75% confluency in 96-well plates.  For 
SNAP, CHO-K1 cells were seeded at 60-75% confluency in 96-well plates.  Cells were 
washed with HBSS and overlaid with either HBSS or pyrenebutyrate and incubated for 5 
minutes at 37˚C.  TMR labeled C-terminal 9R-HaloTag was added so that final protein 
concentration was 50 M, and pyrenebutyrate where present, was at a final concentration 
of 150 M. TMR labeled N- and C-terminal 9R-SNAP was added so that final protein 
concentration was at 5 M and pyrenebutyrate was at a final concentration of 50 M.  
Following incubation at 37˚C for 15 minutes, cells were washed 5 times with HBSS, 
overlaid with Opti-MEM and imaged. 
 
Results 
The protein transfection reagents Chariot and BioPORTER were used to introduce 
the caged FC-Cdc42-HT into HeLa cells and cellular entry was assessed by Western blot 
analysis for either the Cdc42 or HT protein (Figure 7-1). No protein was detected using 
the reagent Chariot (Figure 7-1A and B, lanes 2).  Using the BioPORTER reagent, a faint 
band could be detected when anti-HT antibody was used to probe for protein (Figure 7-
1A, lane 3), however no signal was detected when the anti-Cdc42 antibody was used 
(Figure 7-1B, lane 3).  Because the BioPORTER reagent showed promise in terms of 
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being able, by Western blot analysis, to introduce the caged FC-Cdc42-HT protein into 
HeLa cells, we decided to image cells transfected using BioPORTER to assess the 
intracellular distribution when using this method. 
 
       
 
Figure 7-1.  Westerns following Chariot and BioPORTER treatment. The protein 
transfection reagents Chariot and BioPORTER  were used to introduce the caged FC-
Cdc42-HT into HeLa cells and cellular entry was assessed by Western blot analysis for 
either the Cdc42 or HT protein. No protein was detected using the reagent Chariot (A and 
B, lanes 2).  Using the BioPORTER reagent, a faint band could be detected when anti-HT 
antibody was used to probe for protein (A, lane 3), however no signal was detected when 
the anti-Cdc42 antibody was used.  Lanes 1 in A and B are load controls. 
 
 
 
 To allow us to image cellular entry and localization using the BioPORTER 
reagent, we first had to label the protein to be introduced with a fluorophore.  As the 
caged FC-Cdc42-HT protein is itself not fluorescent, we decided to instead use HT 
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protein that had been labeled using tetramethylrhodamine (TMR) conjugated to the HT 
reactive ligand.  Using this method, we were able to observe very faint fluorescence in 
cells treated with both labeled protein and BioPORTER, but none when cells were treated 
with either on its own.  Unfortunately, the fluorescence was so faint that we could not 
capture images of it.  Furthermore, due to this very weak signal, we were unable to 
determine the localization pattern of the labeled protein. 
 Based on the difficulties we experienced with proteins transfection reagents, we 
attempted to use CPP tagging and pyrenebutyrate methodologies.  We began first by 
fusing an oligoarginine tag consisting of 9 arginines to the C-terminus of HT.  We then 
labeled this tagged HT with HT-TMR dye and treated HeLa cells both in the absence and 
presence of pyrenebutyrate, and imaged the cells to determine the relative localization 
patterns (Figure 7-2).  In cells treated with C-terminal 9R-HT, both in the presence and 
absence of pyrenebutyrate, fluorescence signal appeared punctate, rather than diffuse.  
This suggests that the method of protein entry in both treatment types relied on an 
endosomal uptake pathway.  However, HT protein itself is quite negatively charged, and 
this charge could have an effect on cellular uptake or localization under these conditions.  
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Figure 7-2. Loading of polyarginine-tagged HT into HeLa Cells. HeLa cells treated 
with 50 M 9R-HT labeled with TMR-HT ligand  with and without 150 M PBA were 
imaged by fluorescence microscopy (left) and DIC (right).  For both treatment types, 
cellular localization appeared both diffuse and punctate (left upper and lower panels). 
 
 
 The protein termed SNAP, derived from the human DNA repair protein O6-
methylguanine-DNA methyltransferase, reacts specifically with O6-benzylguanine 
derivatives.  Taking into account the negative charge on HT, we decided to tag the more 
neutral SNAP on the N-and C-termini with 9R polyarginine tags.  We then reacted the 
tagged SNAP proteins with Dy-549 conjugated to a SNAP reactive ligand and introduced 
the labeled and tagged protein into CHO-K1 cells in the presence of pyrenebutyrate (Fig 
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7-3).  Cells treated with both N-and C-terminally oligoarginine tagged SNAP protein in 
the presence of pyrenebutyrate exhibit both diffuse and punctate protein localization 
patterns. In some cases, the SNAP protein was not localized diffusely throughout the cell, 
but appeared to accumulate in what looked to be nucleoli. 
 
 
 
Figure 7-3.  Loading of polyarginine tagged SNAP protein into CHO Cells. CHO 
cells treated with 50 M PBA and 5 M 9R-SNAP labeled with TMR-SNAP ligand were 
imaged by fluorescence microscopy (left) and DIC (right).  For both C-terminally and N-
terminally 9R-tagged SNAP, cellular localization was both diffuse and punctate, often 
localized to what appear to be nucleoli (left upper and lower panels). 
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Discussion 
 We described in CHAPTER VI the generation of a two-step modification system 
whereby a Rho GTPase’s ability to bind GTP and become active could be controlled by 
light in vitro.  To show that this approach could be applied in a cellular context to allow 
for the study of Rho GTPase activation requirements in vivo, we employed several 
established methods of introducing recombinant protein into cells.  Unfortunately, of the 
methods we tried, we saw either unsuccessful (Chariot) or inefficient (BioPORTER) 
results (Figure 7-1), or punctate or localized distribution of proteins (CPPs and 
pyrenebutyrate), rather than diffuse localization (Figure 7-2; Figure 7-3). Potentially one 
of the main challenges associated with the methods we used to introduce protein into 
cells related to the overall amount of protein each method used.  Both transfection 
reagents recommended the introduction of a set, low amount of protein for best results.  
Potentially this amount was too low to allow for protein visualization in the manner we 
were attempting.  In examples where CPPs and pyrenebutyrate were successful, multiple 
applications and/or very high protein concentrations were necessary (Inomata et al., 
2009).  Due to technical constraints inherent to the generation of our caged FC-Cdc42-
HT, application of protein concentrations similar to those reported is not possible.  There 
is also the potential that the issues we observed are directly related to the specific protein 
species being used. 
 While microinjection could overcome some of the limitations presented by the 
other methods we tried, there are additional considerations in terms of using this method 
to introduce Rho GTPases into cells.  This family of proteins is postranslationally 
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modified on their C-terminus and this modification is essential for their proper 
localization and function.  Because the C-terminal posttranslational modification of Rho 
GTPase proteins occurs on a cysteine and our photocage is also cysteine reactive, when 
working with Cdc42 and Rac1 in vitro, we used a C-terminally truncated mutant to 
simplify experimental procedures (CHAPTER VI).  
One possible method to allow for caged GTPase protein to be properly localized 
once introduced into a cell could involve the development of a multi-step modification 
system that would allow for differential modification of the C-terminal cysteine and 
cysteine 18 in the nucleotide binding pocket.  One way to do this would be to block 
cysteine 18 modification by preloading the GTPases with nucleotide and reacting the C-
terminal cysteine with a reversible cysteine modifier, for example [2-
(trimethylammonium) ethyl] methanethiosulfonate  (MTSET).  Cysteine 18 modification 
could be performed as usual after removing nucleotide with EDTA treatment and 
following HT reaction and final chromatographic purification steps, simple DTT 
treatment would remove the MTSET modification and free the C-terminus for proper 
posttranslational modification (Figure 7-4).  An alternate route would be to use a 
mammalian expression system, such as a Baculovirus based expression system, to ensure 
proper posttranslational modification prior to cysteine 18 modification. Microinjection of 
single cells could then be used to introduce the caged GTPase with a free, or properly 
modified, C-terminus to address questions about the spatial and temporal activation 
requirements of Rho GTPases in living cells.  
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Figure 7-4.  Differential cysteine modification scheme.  Preloading full-length GTPase 
with GDP, subsequent modification of the C-terminal cysteine with MTSET, and 
removal of GDP via EDTA treatment results in GTPase with a protected C-terminal 
cysteine and an exposed Cys18.  Modification of Cys18 with 4 (the yellow star) and 
reaction with HT protein, FPLC purification and DTT treatment results in a  GTPase 
modified on Cys18 with 4 and HT, and a free C-terminal cysteine which can be properly 
posttranslationally modified by cellular machinery once introduced into a cell. 
 
 
 While the work reported here was in progress, Klaus Hahn and colleagues 
published a report describing studies using a genetically encoded photoactivatable form 
of Rac1 (Wu et al., 2009b).  Specifically, they genetically fused a flavin binding light 
oxygen voltage 2 (LOV2) domain of the protein phototropin to the N-terminus of a CA 
mutant of Rac1 through a helical extension made up of phototropin’s C-terminus J.  In 
the dark, the LOV2 and J domains interact, sterically blocking CA-Rac1 from 
interacting with effector proteins.  Upon irradiation with light, the J helix unwinds and 
CA-Rac1 is once again able to interact with effector proteins and cause its downstream 
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effects.  Furthermore, upon removal of the light source, LOV2 and J once again interact 
and inhibit CA-Rac1’s activity.  This approach is not without its disadvantages.  In the 
dark state, CA-Rac1 is not completely inhibited, but still signals to a small degree.  Also, 
the fusion itself may effect Rac1 localization and signaling, as well as which subset of 
effectors are both blocked and able to interact with CA-Rac1 upon caging and uncaging.   
However overall, the fact that the fusion is genetically encoded and that activation is 
reversible make it an incredibly powerful tool for the study of Rac1 activation 
requirements.  This approach also has the potential to be applied to the study of other Rho 
and small GTPase family members.  If the two-part selective cysteine modification 
scheme suggested above to generate caged Rho GTPases that are, or could be properly 
modified is successful, the resulting tools would help to further elucidate the roles played 
by the different Rho GTPase family members at different cellular stages and locations. 
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CHAPTER VIII: Using Photocaging to inhibit Rho GTPases 
Introduction  
 The Rho GTPase field has produced a wealth of structural data and information 
regarding the role of specific residues in the function and regulation of the Rho GTPases. 
Described in CHAPTER VI is the development of a two-part modification system where 
modification with a photolabile small molecule that can recruit the much larger HaloTag 
protein blocks nucleotide binding in active mutants of Rho GTPases and allows for their 
subsequent light dependent activation.  Using the available crystallography data and this 
two-part modification system, we attempted to generate GTPases that could be 
inactivated in a spatial and temporal manner by covalent modification of dominant 
negative mutants.  This would allow control over where and when the Rho GTPase is 
turned off.   
DN Rho GTPases function by sequestering GEF away from their endogenous WT 
counterparts and thus preventing their activation.  Based on this, we hypothesized that 
alkylating DN Rho GTPases with a photolabile modification on residues that would block 
GEF binding could allow for the light induced inactivation of endogenous protein.  
Specifically, we hypothesized that alkylating DN mutant T19N of RhoA on mutant 
cysteine residues introduced at Q63 or N41 (RhoA numbering), and recruitment of the 
much larger protein HT, would allow us to prevent its inhibition of endogenous RhoA.  
Irradiation with light would remove the photocage and protein modifications and allow 
the protein to exert its dominant negative effects at the time and place of uncaging. The 
location of these mutated cysteines is such that their modification is likely to prevent 
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interaction of the DN mutant with GEF proteins.  Based on structural data (Snyder et al., 
2002), it appears that amino acids Q63 and N41 do not directly interact with GEF 
proteins, such that mutating them to cysteines would not interfere with GEF binding 
(Figure 8-1).  However, based on their proximity to the GEF binding site, modification of 
the introduced cysteine residues with the photocage and HT protein could prevent GEF 
binding in this region.  Further, it has been shown that Clostridium botulinum exotoxin 
C3 inhibits GEF interaction with RhoA by ADP-ribosylating N41 (Aktories et al., 1992), 
suggesting that modification at this location with a photocage could also prevent GEF 
binding. 
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Figure 8-1.  GEF: GTPase binding interface.  Rho GTPase Cdc42 (white) and GEF 
intersectin (blue).  Residues N41 and Q63 (RhoA numbering) of Cdc42 are highlighted in 
magenta and purple, respectively, and are located at the interface between Cdc42 and 
intersectin, but do not appear to be involved directly in the GTPase:GEF interaction 
(PBD 1KI1). 
 
 
As an alternative, it has been shown that the minimum Cdc42-binding domain of 
the Cdc42 specific tyrosine kinase ACK1 (ACK-42) can bind to GTP-Cdc42 and inhibit 
it by blocking its interaction with effector proteins (Nur et al., 1999). ACK-42 functions 
by wrapping around and masking Cdc42’s effector binding interface.  In addition, this 
binding domain possesses a single cysteine residue.  We hypothesized that caging this 
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cysteine with our photolabile small molecule that can recruit HT could prevent ACK-42 
from interacting with Cdc42 to inhibit it until irradiation with light, upon which uncaging 
would occur and the binding domain could once again function as a Cdc42 inhibitor at 
the location and time of uncaging (Figure 8-2). 
 
 
 
 
Figure 8-2.  Alternate scheme to use light to inhibit a GTPase. The minimum Cdc42-
binding domain of the Cdc42 specific tyrosine kinase ACK1 (ACK42) binds to GTP-
Cdc42, wrapping around it and blocking its interaction with effector proteins.  
Modification of ACK42 on its single cysteine with 4 and HT could potentially block its 
interaction with Cdc42 until uncaging with light, allowing for site specific inactivation of 
Cdc42. 
 
 
 
Materials and Methods 
Plasmid constructs 
Mutant proteins were created using the Quickchange site-directed mutagenesis kit 
(Stratagene). C-terminally truncated RhoA C190S was made by PCR of almost the full-
length gene with the primers gaatggatccatggctgccatccggaagaaactggtg and 
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gaacgaattctcaagacccagattttttcttcccacgtctagc. The RhoA binding domain of the GEF Pdz 
was PCR amplified using the primers gaatggatccgatgcccaaaattggcagcatac and 
gaacgaattcttaggcattccgcacggcctcttc.  These PCR products were then digested with BamHI 
and EcoRI and ligated into the corresponding sites in pGEX6P-1.   
For RhoA: The T19N point mutation was introduced with the primers 
ggtgatggagcctgtggaaagaattgcttgctcatagtcttcagc and 
tcggaagactatgagcaagcaattctttccacaggctccatcacc. The C20S point mutation was introduced 
using the primers ggagcctgtggaaagaacagcttgctcatagtcttcagc and 
gctgaagactatgagcaagctgttctttccacaggctcc . The N41C mutation was introduced using the 
primers tatgtgcccacagtgtttgagtgctatgtggcagatatcgaggtgg and 
ccacctcgatatctgccacatagcactcaaacactgtgggcacatac.  The Q63C mutation was introduced 
using primers gctttgtgggacacagctgggtgtgaagattatgatcgcctgagg and 
cctcaggcgatcataatcttcacacccagctgtgtcccacaaagc. 
 The Cdc42 binding domain of Ack1 (ACK42) comprised of amino acids 504-545 
was PCR amplified using the primers gaatgaattcggcctgtcggcccaggacatc and 
gaacggatccttagttgcccagatacagctcgtcaatcctgtccgggaag. This PCR product was then 
digested with EcoR1 and BamHI and ligated into the corresponding sites in pMAL-c2X. 
 HaloTag constructs were made previously, as described in CHAPTER VI 
(Harwood and Miller, 2009). 
 
Protein expression 
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 RhoA mutants and Pdz were expressed as GST fusion proteins from the vector 
pGEX6P-1 in the BL21(DE3) E. coli strain as previously described (Bhunia and Miller, 
2007).  ACK42 was expressed as a MBP fusion protein from the vector pMAL-c2X in 
the BL21(DE3) E. coli strain just like RhoA mutants.  HaloTag (Promega) was expressed 
as a His6 fusion protein from the vector pET28 in the BL21(DE3) pLysS E. coli strain. 
Cells were grown at 37˚C until the OD600 reached 0.8, then induced with 0.1 mM IPTG 
and incubated at 20˚C overnight.  Cells were pelleted at 5000 rpm in a Sorvall 2C3C Plus 
centrifuge (H600A rotor) at 4˚C for 10 minutes, then flash frozen in liquid nitrogen and 
used immediately or stored at -80˚C, with the exception of Pdz expressing cells, which 
were not flash frozen and were used immediately or stored at -20˚C. 
 
RhoA, Pdz and ACK42 purification 
 E. coli cell pellets from one liter of culture were thawed on ice, resuspended in 25 
ml Lysis Buffer (50 mM Tris or HEPES pH 7.4, 500 mM NaCl, and 0.5% Tween-20) 
containing 1 mM PMSF and, with the exception of Pdz pellets, disrupted by sonification 
(Branson Sonifier). Dithiothreitol (DTT) was added at 10 mM and the resulting cell 
lysate was clarified by centrifugation at 35K rpm in a Beckman 50.2Ti rotor for 1 hour.  
The supernatant was batch-bound to immobilized glutathione or amylose (for ACK42) 
resin for 1h at 4˚C, and then the beads were washed with Lysis Buffer containing 10 mM 
DTT followed by Wash Buffer (50 mM Tris pH 8.1, 250 mM NaCl and 10 mM DTT).   
For RhoA, the beads were then incubated with Nucleotide Removal Buffer (50 mM Tris 
pH 7.4, 150 mM NaCl, 1 mM TCEP, and 20 mM EDTA).  Finally, both RhoA and Pdz 
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beads were washed with Storage Buffer (50 mM HEPES pH 7.4, 50 mM NaCl, 1 mM 
TCEP, and 1 mM EDTA).  Twenty units of PreScission Protease (GE Healthcare) were 
added and incubation continued overnight at 4˚C to cleave the GST fusion and elute the 
untagged GTPase. 
For ACK42, 10 mM maltose in Wash Buffer was used to elute the MBP-tagged 
ACK42, which was then dialyzed against 50 mM HEPES pH 7.4, 50 mM NaCl, 1 mM 
TCEP, and 1 mM EDTA.   
 
HaloTag purification 
 E. coli cell pellets were thawed on ice, resuspended in 50 mM NaPhos pH 7.8, 
500 mM NaCl, 10 mM imidazole, and 0.1% Tween-20 containing 0.2 mM PMSF and 
disrupted by sonification. BME was added at 5 mM and the resulting cell lysate was 
centrifuged at 35K rpm in a Beckman 50.2 Ti rotor for 1 hour at 4˚C.  The clarified 
supernatant was batch-bound to Talon resin (BD Biosciences) for 1 hour at 4˚C.  The 
beads were washed with 50 mM NaPhos pH 7.8, 500 mM NaCl, 30 mM imidazole and 5 
mM BME.   The His6 HaloTag was eluted with 50 mM NaPhos pH 7.8, 500 mM NaCl, 
300 mM imidazole and 5 mM BME, then dialyzed against 50 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM TCEP, and 1 mM EDTA.  
 
Small molecule modification of RhoA and ACK42 
Proteins were incubated with 1-2 mM TCEP to reduce surface exposed cysteines.  
Free TCEP was then removed by passage over two Zeba columns equilibrated with 50 
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mM HEPES pH 7.4, 50 mM NaCl and 5 mM EDTA.   For RhoA, 20 mM MgCl2 and 300 
M GDP were added and the mixture was incubates at 22˚C with shaking at 300 rpm for 
30 minutes.  Ten equivalents of the small molecule photocage 4, prepared as outlined in 
CHAPTER VI, were then added and allowed to react in the dark at 22°C for 3h with 
shaking at 300 rpm (Eppendorf Thermomixer). Unreacted alkylating agent was removed 
by passage over a Zeba column equilibrated with 50 mM Tris pH 7.4, 150 mM NaCl, 
1mM TCEP, and 1 mM EDTA.  
   
Recruitment of HaloTag protein to RhoA or ACK42 modified with 4 
 Protein that had been alkylated with 4 as descried above was incubated with 0.3-
0.5 eq of purified HaloTag protein at 22°C in the dark for 1h with shaking at 300 rpm. 
The HaloTag-modified protein was purified by FPLC (AKTA) on a MonoQ ion-
exchange column (GE Healthcare).  The purity of the fractions was assessed by SDS-
PAGE with Coomassie staining. Purified HaloTag-modified GTPase was used directly 
for GEF exchange assays. 
 
GEF exchange assays 
 Measurements were taken in a Spex FluoroMax-3 fluorimeter every second with a 
0.1 second integration time for a total of 400 seconds.  Excitation was at 488 and 
emission was at 508.5, slits were set at 5.  RhoA C190S protein was preloaded with 
saturating concentrations of GDP in the presence of 2 mM MgCl2.  Excess GDP was 
removed by passage over 2 Zeba column equilibrated with 50 mM Tris pH 7.4, 150 mM 
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NaCl, 1mM TCEP, and 1 mM MgCl2.  The GEF exchange assay was initiated by the 
rapid addition of 1 M GDP-RhoA C190S into GEF assay buffer (20 mM Tris pH 7.5, 50 
mM NaCl, 5 mM MgCl2, 1 mM TCEP, 5% glycerol, and 10 mg/mL BSA) containing A) 
500 nM Bodipy-FL GTP,  B) 500 nM Bodipy-FL GTP and 100 nM Pdz, C) 500 nM 
Bodipy-FL GTP, 100 nM Pdz, and 10 M RhoA T19N/C20S/Q63C/C190S, or D) 500 
nM Bodipy-FL GTP, 100 nM Pdz, and 10 M HT caged RhoA 
T19N/C20S/Q63C/C190S. 
 
Results and Discussion 
We hypothesized that we could photocage the DN activity of DN Rho GTPases 
by using a two-part modification system whereby we alkylate them with a small molecule 
that can then recruit the much larger HT protein.  This alkylation would occur on mutated 
cysteines at locations that appear to be at the interface between the GTPase RhoA and 
GEF protein, but which didn’t appear to make any critical contacts.  To do this, we 
introduced cysteine mutations into the DN T19N background of RhoA at position N41 
and Q63.  Unfortunately, the T19N/N41C mutant did not appear to be stable upon 
expression and purification.  Because T19N/Q63C behaved more consistently, we 
proceeded to also mutate the cysteine in the nucleotide binding pocket to a serine, C20S.  
We also mutated the C-terminal CAAX box cysteine to a serine, C190S, and removed the 
final three amino acids.   
Because we had introduced many mutations into the DN RhoA protein, we 
wanted first to determine if it was still able to behave in a DN manner.  To assess this, we 
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performed GEF nucleotide exchange assays.  In solution, the fluorescence of Bodipy-FL 
GTP is quenched by the close proximity of the GTP portion of the molecule.  However, 
upon GEF loading of Bodipy-FL GTP into the GTPase, quenching is relieved and an 
increase in fluorescence intensity is observed.  Thus, fluorescence intensity can be used 
as a measure of nucleotide loading of the GTPase.  We took advantage of these properties 
of Bodipy-FL GTP to determine if the mutated DN RhoA, T19N/C20S/Q63C/C190S, 
was still able to bind to GEF protein and sequester it away from WT RhoA, preventing 
the GEF from loading WT RhoA with nucleotide.  To do this, we preincubated the RhoA 
GEF Pdz with the mutated DN RhoA and Bodipy-FL GTP, and rapidly added GDP 
loaded WT-RhoA and measured fluorescence intensity.  When GDP WT-RhoA is added 
to buffer containing Bodipy-FL GTP in the absence of GEF protein, very slow nucleotide 
exchange occurs, resulting in a very small increase in fluorescence (Fig 8-3).  However, 
when GDP WT-RhoA is added to buffer containing both Bodipy-FL GTP and the GEF 
Pdz, a rapid increase in florescence intensity occurs as Pdz exchanges the fluorescent 
nucleotide for GDP in the nucleotide binding pocket of RhoA (Fig 8-3).  When   GDP 
WT-RhoA is added to buffer containing Bodipy-FL GTP and mutated DN RhoA 
preincubated with Pdz, very little increase in fluorescence intensity occurs (Fig 8-3), 
indicating that the mutated DN RhoA is indeed still behaving as a DN mutant and 
sequestering Pdz away from the WT RhoA. 
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Figure 8-3.  Photocaging DN RhoA: GEF nucleotide exchange assays. Rapid addition 
of WT RhoA-GDP to Bodipy-FL GTP in buffer results in a minimal increase in 
fluorescence (red).  Addition of RhoA-GDP to  a mixture of Bodipy-FL GTP and the 
GEF Pdz results in an increase in fluorescence intensity as Pdz loads RhoA with the 
fluorescent GTP analog (green).  The DN RhoA mutant is able to bind Pdz and inhibit its 
ability to load WT-RhoA with Bodipy-FL GTP, as evidenced by the minimal increase in 
fluorescence observed upon rapid addition of WT RhoA-GDP to  a DN-RhoA/Pdz 
mixture (blue).  Based on the partial increase in fluorescence intensity that occurs upon 
addition of WT RhoA-GDP to a mixture of Pdz and the DN mutant modified with 4 and 
HT (orange), the modification only partially blocks it inhibition of Pdz. 
 
 
We then wanted to determine if modification of Q63C in DN RhoA with our 
photolabile small molecule and HT protein would block its ability to interact with Pdz, 
thus blocking its dominant negative activity in a way that could be reversed with light.  
Using the same GEF nucleotide exchange assay as above, we preincubated 
T19N/C20S/Q63C/C190S that had been alkylated with 4, reacted with the HaloTag 
protein, and purified by FPLC with Pdz and Bodipy-FL GTP.  If the two-part 
modification system is able to block Pdz binding, upon rapid addition of GDP WT-RhoA, 
an increase in fluorescence intensity similar to that seen when adding GDP WT-RhoA to 
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Pdz alone should be observed.  However, when we conducted this experiment, we only 
observed a partial recovery in fluorescence intensity (Fig. 8-3).  This could be due to the 
initial small molecule modification occurring on not just Q63C, but another cysteine as 
well, since RhoA possesses other cysteines including C16 and C105. However, the 
observed molecular weight of the RhoA-HT fusion product suggest that only one HT 
molecule reacted with each RhoA protein.  This does not mean, however, that the 
modification occurred on the same cysteine in all cases.  Potentially, multiple photocage 
molecules could have reacted with different cysteines, but once the large HT protein 
reacts with one of the cages, it sterically blocks the reaction of another HT protein. 
Unfortunately, efforts to analyze tryptic and chymotryptic digests of caged RhoA 
using mass spectrometry did not allow us to identify which specific cysteine or cysteines 
the cage was modifying, since we could not see the peptides containing the cysteines.  
LC/ESI-MS of one caged mutant, RhoA T19N/Q63C/C190S, revealed that when the 
protein was loaded with excess GDP, it was only modified by 4 once (Fig 8-4).  If 
multiple cysteines on the protein were surface exposed and could be modified, you would 
expect to see a +1, +2, +3 charge state etc. since 10 fold molar excess of cage was present 
during alkylation.  However, it is difficult to interpret this data as C20, the cysteine 
corresponding to C18 in Cdc42, is present in this mutant where it was not in the mutant 
used for the GEF nucleotide exchange assays. 
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fragment termed ACK42 can specifically bind to GTP-Cdc42 and prevent it from 
interacting with and signaling through its other effectors (Figure 8-2) (Nur et al., 1999).  
Additionally, this fragment of Ack1 possesses a single cysteine residue.  Based on this, 
we predicted that if we modified that cysteine with 4, and recruited the HT protein, we 
could block the ability of ACK42 to inhibit Cdc42 until we irradiate with light at a 
specific time and location.  To do this, we expressed ACK42 as a MBP fusion protein, 
modified it with 4, reacted it with HT and purified the fusion using FPLC (Figure 8-5).   
 
   
 
 
Figure 8-5.  SDS-Page of fractions collected during FPLC purification of Ack-4-HT. 
All fractions that contained the Ack-4-HT fusion (upper bands) also contained a 
contaminant from the Ack purification mixture (lower bands). 
 
 
Unfortunately, MBP-ACK42 is itself very unstable and difficult to work with.  It 
is highly prone to dimerization through disulfide bonds, and degrades readily upon 
purification (Figure 8-6).  Efforts to generate purified fusion protein were also 
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complicated by issues with contamination and degradation (Figure 8-7).  Potentially the 
spacing between ACK42 and the MBP tag contributed to the inherent instability of the 
fusion.  Attempts to optimize linker spacing and potentially the specific tag used could 
rectify some of the problems ACK42 presents.  One interesting approach would be to 
append a fluorescent protein onto ACK42, and equip HT with a quencher such that upon 
uncaging, the location of Cdc42 being actively inhibited by ACK42 could be visualized. 
 
 
 
 
 
 
 
 
 
 

 150 
 
 
Figure 8-7.  ACK42 and Ack-4-HT are prone to degradation.  ACK42 (lane 1) is 
contaminated by degradation products, as is the Ack-4-HT reaction product mixture (lane 
2). 
 
 
Overall, while our efforts to generate a species that could allow for the light 
induced inhibition of a Rho GTPase were not ultimately successful, with some 
optimization, our approaches could eventually prove fruitful.  A Rho GTPase that could 
be “turned off” with light would be a nice counterpart for GTPases that can be “turned 
on” when asking questions about the spatial and temporal activation requirements of this 
family of proteins. 
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CHAPTER IX: Photocontrol of Rho GTPases: Disucssion 
Many methods to control the activation states of proteins have been developed.  A 
powerful example of one of these methods is the use of photocaging.  Photocaging is 
particularly powerful when applied to proteins whose activation at specific times and 
locations in the cell is essential for proper cellular functioning.  One such example is the 
family of proteins called the Rho GTPases.  CHAPTER VI describes the application of 
photocaging to the control of GTP binding in active mutants of Cdc42 and Rac1.  In this 
manner, GTPases that could be turned on at specific times and locations with light were 
generated.  It is likely that the same approach would be effective in photocaging other 
Rho GTPase family members as well. 
CHAPTER VII describes attempts to use several reported methods to introduce 
the caged GTPases into cells to verify the ability to uncage and activate them in vivo.  
Unfortunately, these methods were either unsuccessful or inefficient.  The use of these 
caged GTPases in cells is further complicated by the requirement of posttranslational 
modifications necessary for their proper functioning.  Future work to develop methods to 
allow for the differential modification of the C-terminal cysteine and Cys18 in these 
GTPases would facilitate the generation of photocaged GTPases with a free C-terminal 
cysteine that could be properly posttranslationally modified upon microinjection, for 
example, and allow for in vivo studies with these proteins. 
Finally, CHAPTER VIII describes attempts to use photocaging to turn off a Rho 
GTPase.  To do this, DN Rho GTPases were modified at a location predicted to block 
GEF binding until irradiation with light.  Upon irradiation, the DN GTPases would bind 
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and sequester all GEF at the location of uncaging, thus preventing the activation of 
endogenous GTPase and allow questions about the GTPases activation requirement at 
that time and place to be addressed.  Unfortunately, while photocaging was able to 
partially block GEF interaction, the block was not complete.  Photocaging another 
residue at the GTPase:GEF interface may prove more successful.  In addition, attempts to 
photocage an effector binding domain (ACK42) that can bind to and mask the effector 
biding interface of Cdc42, thus inhibiting Cdc42 activity, were also unsuccessful.  
Methods to stabilize ACK42, perhaps optimization of linker length between ACK42 and 
its purification tag, may allow for its photocaging and use to probe questions regarding 
Cdc42’s spatiotemporal activation requirements. 
Overall, this thesis describes the development of tools that could allow for both 
the better visualization of the cellular environment as well as the better control of cellular 
functioning through the precise control of protein activity.  Applying these tools, and 
others like them, to the study of cellular biology will allow for an improved 
understanding of the regulatory processes involved in the control of key events important 
to maintaining cellular homeostasis, as well as the events that go awry, ultimately leading 
to the development of disease states.  The interface between chemistry and biology 
presents unique advantages in the development of such tools. 
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